These terms and conditions govern your use of the website alphaminr.com and its related
services.
These Terms and Conditions (“Terms”) are a binding contract between you and Alphaminr,
(“Alphaminr”, “we”, “us” and “service”). You must agree to and accept the Terms. These Terms
include the provisions in this document as well as those in the Privacy Policy. These terms may
be modified at any time.
Subscription
Your subscription will be on a month to month basis and automatically renew every month. You may
terminate your subscription at any time through your account.
Fees
We will provide you with advance notice of any change in fees.
Usage
You represent that you are of legal age to form a binding contract. You are responsible for any
activity associated with your account. The account can be logged in at only one computer at a
time.
The Services are intended for your own individual use. You shall only use the Services in a
manner that complies with all laws. You may not use any automated software, spider or system to
scrape data from Alphaminr.
Limitation of Liability
Alphaminr is not a financial advisor and does not provide financial advice of any kind. The
service is provided “As is”. The materials and information accessible through the Service are
solely for informational purposes. While we strive to provide good information and data, we make
no guarantee or warranty as to its accuracy.
TO THE EXTENT PERMITTED BY APPLICABLE LAW, UNDER NO CIRCUMSTANCES SHALL ALPHAMINR BE LIABLE TO
YOU FOR DAMAGES OF ANY KIND, INCLUDING DAMAGES FOR INVESTMENT LOSSES, LOSS OF DATA, OR ACCURACY
OF DATA, OR FOR ANY AMOUNT, IN THE AGGREGATE, IN EXCESS OF THE GREATER OF (1) FIFTY DOLLARS OR
(2) THE AMOUNTS PAID BY YOU TO ALPHAMINR IN THE SIX MONTH PERIOD PRECEDING THIS APPLICABLE
CLAIM. SOME STATES DO NOT ALLOW THE EXCLUSION OR LIMITATION OF INCIDENTAL OR CONSEQUENTIAL OR
CERTAIN OTHER DAMAGES, SO THE ABOVE LIMITATION AND EXCLUSIONS MAY NOT APPLY TO YOU.
If any provision of these Terms is found to be invalid under any applicable law, such provision
shall not affect the validity or enforceability of the remaining provisions herein.
Privacy Policy
This privacy policy describes how we (“Alphaminr”) collect, use, share and protect your personal
information when we provide our service (“Service”). This Privacy Policy explains how
information is collected about you either directly or indirectly. By using our service, you
acknowledge the terms of this Privacy Notice. If you do not agree to the terms of this Privacy
Policy, please do not use our Service. You should contact us if you have questions about it. We
may modify this Privacy Policy periodically.
Personal Information
When you register for our Service, we collect information from you such as your name, email
address and credit card information.
Usage
Like many other websites we use “cookies”, which are small text files that are stored on your
computer or other device that record your preferences and actions, including how you use the
website. You can set your browser or device to refuse all cookies or to alert you when a cookie
is being sent. If you delete your cookies, if you opt-out from cookies, some Services may not
function properly. We collect information when you use our Service. This includes which pages
you visit.
Sharing of Personal Information
We use Google Analytics and we use Stripe for payment processing. We will not share the
information we collect with third parties for promotional purposes.
We may share personal information with law enforcement as required or permitted by law.
x
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended
September 30, 2025
OR
☐
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from ______ to ______
Commission File Number
001-42125
Waystar Holding Corp.
(Exact name of registrant as specified in its charter)
Delaware
84-2886542
(State or other jurisdiction of
incorporation or organization)
(I.R.S. Employer
Identification No.)
1550 Digital Drive, #300
Lehi
,
Utah
84043
84043
(Address of principal executive offices)
(Zip Code)
(
844
)
492-9782
Registrant’s telephone number, including area code
Not applicable
(Former name, former address and former fiscal year, if changed since last report)
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading Symbol(s)
Name of each exchange on which registered
Common Stock, par value $0.01 per share
WAY
The Nasdaq Stock Market LLC
Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports); and (2) has been subject to such filing requirements for the past 90 days.
Yes
x
No
☐
Indicate by check mark whether the registrant has submitted electronically and posted on its corporate web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).
Yes
x
No
☐
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act. (Check one):
Large accelerated filer
☐
Accelerated filer
☐
Non-accelerated filer
x
Smaller reporting company
☐
Emerging growth company
x
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
☐
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act). Yes
☐
No
x
The registrant had outstanding
191,316,583
shares of common stock as of October 20, 2025.
The following definitions apply to these terms as used in this Quarterly Report on Form 10-Q:
“AI” means artificial intelligence;
“Bain” means those certain investment funds of Bain Capital, LP and its affiliates;
“CPPIB” means Canada Pension Plan Investment Board;
“Credit Facilities” means, collectively, the First Lien Credit Facility, the Revolving Credit Facility, and the Receivables Facility;
“Derby Topco” means Derby TopCo Partnership LP, our direct parent entity prior to the Equity Distribution, in which the Institutional Investors, other equity holders, and certain members of management previously held equity interests;
“EQT” means those certain investment funds of EQT AB and its affiliates;
“Equity Distribution” means the distribution of shares of common stock of the Company held by Derby TopCo to the limited partners of Derby TopCo in accordance with the limited partnership agreement of Derby Topco, which distribution occurred in connection with our initial public offering. Following the Equity Distribution, EQT, CPPIB, Bain, and other equity holders, including members of management, directly hold shares of common stock of the Company;
“Exchange Act” means the U.S. Securities Exchange Act of 1934, as amended;
“First Lien Credit Facility” means the term loan credit facility under the first lien credit agreement, dated as of October 22, 2019, by and among Waystar Technologies, Inc. and the lenders party thereto, as amended from time to time;
“GAAP” means U.S. generally accepted accounting principles;
“Institutional Investors” means EQT, CPPIB, and Bain, and their respective affiliates;
“JOBS Act” means the U.S. Jumpstart Our Business Startups Act of 2012, as amended;
“Net Revenue Retention Rate” means the total amount invoiced to clients in a given twelve-month period divided by the total amount invoiced to those same clients from the prior twelve-month period. See “Management’s Discussion and Analysis of Financial Condition and Results of Operations—Key Performance Metrics and Non-GAAP Financial Measures—Net Revenue Retention Rate”;
“2024 Form 10-K” means the 2024 Form 10-K filed with the SEC by Waystar Holding Corp. on February 18, 2025;
“Receivables Facility” means the receivables facility under the receivables financing agreement, dated as of August 13, 2021, by and among Waystar RC LLC, PNC Bank, National Association, as administrative agent, Waystar Technologies, Inc., as initial servicer, and PNC Capital Markets LLC, as structuring agent, as amended from time to time;
“Revolving Credit Facility” means the revolving credit facility under the first lien credit agreement, dated as of October 22, 2019, by and among Waystar Technologies, Inc. and the lenders party thereto, as amended from time to time;
“SEC” means the U.S. Securities and Exchange Commission;
“Second Lien Credit Facility” means the term loan credit facility under the second lien credit agreement, dated as of October 22, 2019, by and among Waystar Technologies, Inc. and the lenders party thereto, as amended from time to time;
“Securities Act” means the U.S. Securities Act of 1933, as amended;
“SOFR” means the Secured Overnight Financing Rate; and
“Waystar,” the “Company,” “we,” “us,” and “our” mean the business of Waystar Holding Corp. and its subsidiaries.
Certain numerical figures have been subject to rounding adjustments. Accordingly, numerical figures shown as totals in various tables may not be arithmetic aggregations of the figures that precede them.
This report contains forward-looking statements, within the meaning of the Private Securities Litigation Reform Act of 1995, that reflect our current views with respect to, among other things, our operations and financial performance. Forward-looking statements include all statements that are not historical facts. These forward-looking statements are included throughout this report and relate to matters such as our industry, business strategy, goals, and expectations concerning our market position, future operations, margins, profitability, capital expenditures, liquidity, and capital resources and other financial and operating information. We have used the words “anticipate,” “assume,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “future,” “will,” “seek,” “foreseeable,” the negative version of these words or similar terms and phrases to identify forward-looking statements in this report.
The forward-looking statements contained in this report are based on management’s current expectations and are not guarantees of future performance. The forward-looking statements are subject to various risks, uncertainties, assumptions, or changes in circumstances that are difficult to predict or quantify. Our expectations, beliefs, and projections are expressed in good faith and we believe there is a reasonable basis for them. However, there can be no assurance that management’s expectations, beliefs, and projections will result or be achieved. Actual results may differ materially from these expectations due to changes in global, regional, or local economic, business, competitive, market, regulatory, and other factors, many of which are beyond our control. We believe that these factors include but are not limited to the following:
•
our operation in a highly competitive industry;
•
our ability to retain our existing clients and attract new clients;
•
our ability to successfully execute on our business strategies in order to grow;
•
our ability to accurately assess the risks related to acquisitions and successfully integrate acquired businesses, including the acquisition of Iodine Software Holdings, Inc. (“Iodine”);
•
our ability to establish and maintain strategic relationships;
•
the growth and success of our clients and overall healthcare transaction volumes;
•
consolidation in the healthcare industry;
•
our selling cycle of variable length to secure new client agreements;
•
our implementation cycle that is dependent on our clients’ timing and resources;
•
our dependence on our senior management team and certain key employees, and our ability to attract and retain highly skilled employees;
•
the accuracy of the estimates and assumptions we use to determine the size of our total addressable market;
•
our ability to develop and market new solutions, or enhance our existing solutions, to respond to technological changes, or evolving industry standards;
•
the interoperability, connectivity, and integration of our solutions with our clients’ and their vendors’ networks and infrastructures;
•
the performance and reliability of internet, mobile, and other infrastructure;
•
the consequences if we cannot obtain, process, use, disclose, or distribute the highly regulated data we require to provide our solutions;
•
our reliance on certain third-party vendors and providers;
•
any errors or malfunctions in our products and solutions;
•
failure by our clients to obtain proper permissions or provide us with accurate and appropriate information;
•
the potential for embezzlement, identity theft, or other similar illegal behavior by our employees or vendors, and a failure of our employees or vendors to observe quality standards or adhere to environmental, social, and governance standards;
•
our compliance with the applicable rules of the National Automated Clearing House Association and the applicable requirements of card networks;
•
increases in card network fees and other changes to fee arrangements;
•
the effect of payer and provider conduct which we cannot control;
•
privacy concerns and security breaches or incidents relating to our platform;
•
the complex and evolving laws and regulations regarding privacy, data protection, and cybersecurity;
•
our ability to adequately protect and enforce our intellectual property rights;
•
our ability to use or license data and integrate third-party technologies;
•
our use of “open source” software;
•
legal proceedings initiated by third parties alleging that we are infringing or otherwise violating their intellectual property rights;
•
claims that our employees, consultants, or independent contractors have wrongfully used or disclosed confidential information of third parties;
•
the heavily regulated industry in which we conduct business;
•
the uncertain and evolving healthcare regulatory and political framework;
•
health care laws and data privacy and security laws and regulations governing our Processing of personal information;
•
reduced revenues in response to changes to the healthcare regulatory landscape;
•
legal, regulatory, and other proceedings that could result in adverse outcomes;
•
consumer protection laws and regulations;
•
contractual obligations requiring compliance with certain provisions of Bank Secrecy Act/anti-money laundering laws and regulations;
•
existing laws that regulate our ability to engage in certain marketing activities;
•
our full compliance with website accessibility standards;
•
any changes in our tax rates, the adoption of new tax legislation, or exposure to additional tax liabilities;
•
limitations on our ability to use our net operating losses to offset future taxable income;
•
losses due to asset impairment charges;
•
restrictive covenants in the agreements governing our Credit Facilities;
•
interest rate fluctuations;
•
unavailability of additional capital on acceptable terms or at all;
•
the impact of general macroeconomic conditions;
•
our history of net losses and our ability to achieve or maintain profitability;
•
the interests of the Institutional Investors may be different than the interests of other holders of our securities;
•
our status as an “emerging growth company” and whether the reduced disclosure requirements applicable to “emerging growth companies” will make our common stock less attractive to investors; and
•
the other factors described elsewhere in this report, including under the headings “Management’s Discussion and Analysis of Financial Condition and Results of Operations,” “Quantitative and Qualitative Disclosures About Market Risk” and Part II, Item 1A, “Risk Factors” or as described under the heading “Risk factors” in our 2024 Form 10-K, or as described in the other documents and reports we file with the SEC.
These factors should not be construed as exhaustive and should be read in conjunction with the other cautionary statements that are included in this report. Should one or more of these risks or uncertainties materialize, or should any of our assumptions prove incorrect, our actual results may vary in material respects from those projected in these forward-looking statements.
Any forward-looking statements made by us in this report speak only as of the date of this report and are expressly qualified in their entirety by the cautionary statements included in this report. Factors or events that could cause our actual results to differ may emerge from time to time, and it is not possible for us to predict all of them. You should not place undue reliance on our forward-looking statements. We undertake no obligation to publicly update or review any forward-looking statement, whether as a result of new information, future developments, or otherwise, except as may be required by any applicable securities laws.
Investors and others should note that we routinely announce financial and other material information using our Investor Relations website (investors.waystar.com), SEC filings, press releases, public conference calls and webcasts. We use these channels of distribution to communicate with our investors and members of the public about our company, our services and other items of interest. Information contained on our website is not part of this report or our other filings with the SEC.
Unaudited Condensed Consolidated Balance Sheets (in Thousands, Except for Share and Per Share Data)
September 30, 2025
December 31, 2024
Assets
Current assets
Cash and cash equivalents
$
421,056
$
182,133
Restricted cash
24,301
22,449
Accounts receivable, net of allowance of $
5,895
at September 30, 2025 and $
5,885
at December 31, 2024
145,675
145,235
Income tax receivable
—
2,838
Prepaid expenses
20,557
14,414
Other current assets
1,993
3,972
Total current assets
613,582
371,041
Property, plant and equipment, net
48,172
46,731
Operating lease right-of-use assets, net
11,026
10,820
Intangible assets, net
954,967
1,039,049
Goodwill
3,019,999
3,019,999
Deferred costs
90,131
82,815
Other long-term assets
8,479
6,549
Total assets
$
4,746,356
$
4,577,004
Liabilities and stockholders’ equity
Current liabilities
Accounts payable
$
51,401
$
47,365
Accrued compensation
28,300
31,589
Aggregated funds payable
23,848
22,059
Other accrued expenses
26,757
15,930
Deferred revenue
9,018
10,527
Current portion of long-term debt
11,099
11,311
Related party current portion of long-term debt
569
357
Current portion of operating lease liabilities
5,687
5,591
Current portion of finance lease liabilities
973
904
Total current liabilities
157,652
145,633
Long-term liabilities
Deferred tax liability
123,034
100,523
Long-term debt, net, less current portion
1,158,411
1,185,411
Related party long-term debt, net, less current portion
55,783
35,211
Operating lease liabilities, net of current portion
11,855
13,133
Finance lease liabilities, net of current portion
10,549
11,290
Deferred revenue - long-term
5,385
5,739
Other long-term liabilities
1,091
278
Total liabilities
1,523,760
1,497,218
Commitments and contingencies (Note 19)
Stockholders’ equity
Preferred stock $
0.01
par value -
100,000,000
and
100,000,000
shares authorized as of September 30, 2025 and December 31, 2024, respectively;
zero
shares issued or outstanding as of September 30, 2025 and December 31, 2024, respectively
—
—
Common stock $
0.01
par value -
2,500,000,000
and
2,500,000,000
shares authorized at September 30, 2025 and December 31, 2024, respectively;
174,667,840
and
172,108,240
shares issued and outstanding at September 30, 2025 and December 31, 2024, respectively
1,747
1,722
Additional paid-in capital
3,350,190
3,298,083
Accumulated other comprehensive income (loss)
(
542
)
881
Accumulated deficit
(
128,799
)
(
220,900
)
Total stockholders’ equity
3,222,596
3,079,786
Total liabilities and stockholders’ equity
$
4,746,356
$
4,577,004
The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.
Unaudited Condensed Consolidated Statements of Comprehensive Income (Loss) (in Thousands)
Three months ended September 30,
Nine months ended September 30,
2025
2024
2025
2024
Net income/(loss)
$
30,648
$
5,413
$
92,101
$
(
38,204
)
Other comprehensive income (loss), before tax:
Interest rate swaps
(
179
)
(
14,440
)
(
1,868
)
(
20,624
)
Available-for-sale securities
32
—
—
—
Income tax effect:
Interest rate swaps
44
3,506
445
5,014
Available-for-sale securities
(
8
)
—
—
—
Other comprehensive income/(loss), net of tax
(
111
)
(
10,934
)
(
1,423
)
(
15,610
)
Comprehensive income/(loss), net of tax
$
30,537
$
(
5,521
)
$
90,678
$
(
53,814
)
(1)
Amounts reclassified out of accumulated other comprehensive income/(loss) into net interest expense included $
2,171
and $
8,788
for the three months ended September 30, 2025 and 2024, respectively, and included $
4,060
and $
26,085
for the nine months ended September 30, 2025 and 2024, respectively.
(2)
The income tax effects of amounts reclassified out of accumulated other comprehensive income/(loss) were ($
534
) and ($
2,134
) for the three months ended September 30, 2025 and 2024, respectively, and $(
999
) and $(
6,334
) for the nine months ended September 30, 2025 and 2024, respectively.
The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.
Notes to Unaudited Condensed Consolidated Financial Statements
1.
Business
Waystar Holding Corp. (“Waystar”, “we”, “us” or “our”) is a provider of mission-critical cloud technology to healthcare organizations. Our enterprise-grade platform transforms the complex and disparate processes comprising healthcare payments received by healthcare providers from payers and patients, from pre-service engagement through post-service remittance and reconciliation. Our platform enhances data integrity, eliminates manual tasks, and improves claim and billing accuracy, which results in better transparency, reduced labor costs, and faster, more accurate reimbursement and cash flow. The market for our solutions extends throughout the United States and includes Puerto Rico and other U.S. Territories.
Risks and Uncertainties—
We are subject to risks common to companies in similar industries, including, but not limited to, our operation in a highly competitive industry, our ability to retain our existing clients and attract new clients, our ability to establish and maintain strategic relationships, the growth and success of our clients and overall healthcare transaction volumes, consolidation in the healthcare industry, our selling cycle of variable length to secure new client agreements, our implementation cycle that is dependent on our clients’ timing and resources, our ability to develop and market new solutions, or enhance our existing solutions, to respond to technological changes or evolving industry standards, the interoperability, connectivity, and integration of our solutions with our clients’ and their vendors’ networks and infrastructures, the performance and reliability of internet, mobile, and other infrastructure, the consequences if we cannot obtain, process, use, disclose, or distribute the highly regulated data we require to provide our solutions, impact of government regulations on our market, and our reliance on certain third-party vendors and providers.
On occasion, we enter into standard indemnification arrangements in the ordinary course of business. Pursuant to these arrangements, we indemnify, hold harmless, and agree to reimburse the indemnified parties for losses suffered or incurred by the indemnified party, in connection with any trade secret, copyright, patent, or other intellectual property infringement claim by any third-party with respect to its technology. The terms of these indemnification agreements are generally perpetual any time after the execution of the agreement. The maximum potential future payments we could be required to make under these agreements is not determinable because it involves claims that may be made against us in the future but have not yet been made. Historically, we have not incurred costs to defend lawsuits or settle claims related to these indemnification agreements.
We have entered into agreements with our directors or officers that may require us to indemnify them against liabilities that may arise by reason of their status or service as directors or officers, other than liabilities arising from their willful misconduct.
No liability associated with such indemnifications was recorded as of September 30, 2025 and December 31, 2024.
2.
Summary of Significant Accounting Policies
Basis of Financial Statement Presentation
The financial statements include the consolidated balance sheets, statements of operations, statements of comprehensive income (loss), statements of changes in stockholders’ equity, and statements of cash flows of Waystar and its subsidiaries and have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”).
The accompanying unaudited consolidated financial statements and notes have been prepared in accordance with GAAP and applicable rules and regulations of the Securities and Exchange Commission (“SEC”) regarding interim financial reporting. Accordingly, they do not include all of the information and notes required by GAAP for complete financial statements. In the opinion of management, the interim financial information includes all adjustments of a normal recurring nature necessary for a fair presentation of the Company’s financial position, results of operations, changes in stockholders’ equity and cash flows. The results of operations for the nine months ended September 30, 2025 are not necessarily indicative of the results for the full year or the results for any future periods. These unaudited consolidated financial statements should be read in conjunction with the audited consolidated financial statements and related notes for the year ended December 31, 2024 in the 2024 Annual Report of Form 10-K filed with the SEC on February 18, 2025 (the “2024 Annual Report”).
Notes to Unaudited Condensed Consolidated Financial Statements
Use of Estimates
The preparation of the consolidated financial statements in conformity with GAAP requires us to make estimates and assumptions. These estimates and assumptions affect the reported amounts of assets and liabilities, the disclosures of contingent assets and liabilities as of the date of the financial statements, and the reported amounts of revenues and expenses during the reporting periods. Significant estimates and assumptions are used for, but are not limited to: (1) revenue recognition, including estimated expected customer life; (2) recoverability of accounts receivable and taxes receivable; (3) impairment assessment of goodwill and long-lived intangible assets; (4) fair value of intangibles acquired in business combinations; (5) litigation reserves; (6) depreciation and amortization; (7) fair value of stock options issued to employees and assumed as part of business combinations; (8) fair value of interest rate swaps; and (9) leases, including incremental borrowing rate. Future events and their effects cannot be predicted with certainty, and accordingly, accounting estimates require the exercise of judgment. We evaluate and update assumptions and estimates on an ongoing basis and may employ outside experts to assist in evaluations. Actual results could differ from the estimates used.
Revenue Recognition
We derive revenue primarily from providing access to our solutions for use in the healthcare industry and in doing so generate two types of revenue: (i) subscription revenue and (ii) volume-based revenue, which account for
99
% of total revenue for all periods presented. We also derive revenue from implementation fees for our software, as well as hardware sales to facilitate patient payments.
We recognize revenue in accordance with ASC Topic 606,
Revenue from Contracts with Customers
(“ASC 606”), through the following five steps:
•
identification of the contract, or contracts, with a client;
•
identification of the performance obligations in the contract;
•
determination of the transaction price;
•
allocation of the transaction price to the performance obligations in the contract; and
•
recognition of revenue when, or as, we satisfy a performance obligation
Our customers, referred to as clients elsewhere in this report, represent healthcare providers across all types of care settings, including physician practices, clinics, surgical centers, and laboratories, as well as large hospitals and health systems.
We account for a contract when it has approval and commitment from both parties, the rights of the parties are identified, payment terms are identified, the contract has commercial substance and collectability of consideration is probable. The length of our contracts vary but are typically
two
to
three years
and generally renew automatically for successive
one-year
terms. Our revenue is reported net of applicable sales and use tax and is recognized as, or when, control of these services or products are transferred to clients, in an amount that reflects the consideration we expect to be entitled to in exchange for the contract’s performance obligations.
Revenue from our subscription services as well as from our volume-based services represents a single promise to provide continuous access (i.e., a stand-ready obligation) to our software solutions in the form of a service. Our software products are made available to our clients via a cloud-based, hosted platform where our clients do not have the right or practical ability to take possession of the software. As each day of providing access to the software solutions is substantially the same and the client simultaneously receives and consumes the benefits as services are provided, these services are viewed as a single performance obligation composed of a series of distinct daily services.
Revenue from our subscription services is recognized over time on a ratable basis over the contract term beginning on the date that the service is made available to the client. Volume-based services are priced based on transaction, dollar volume or provider count in a given period. Given the nature of the promise is based on unknown quantities or outcomes of services to be performed over the contract term, the volume-based fee is determined to be variable consideration. The volume-based transaction fees are recognized each day using a time- elapsed output method based on the volume or transaction count at the time the clients’ transactions are processed.
Notes to Unaudited Condensed Consolidated Financial Statements
Our other services are generally related to implementation activities across all solutions and hardware sales to facilitate patient payments. Implementation services are not considered performance obligations as they do not provide a distinct service to clients without the use of our software solutions. As such, implementation fees related to our solutions are billed upfront and recognized ratably over the customer's life. Implementation fees and hardware sales represent less than
1
% of total revenue for all periods presented.
Our contracts with clients typically include various combinations of our software solutions. Determining whether such software solutions are considered distinct performance obligations that should be accounted for separately versus together requires significant judgment. Specifically, judgment is required to determine whether access to the Company’s SaaS solutions is distinct from other services and solutions included in an arrangement.
We follow the requirements of ASC 606-10-55-36 through -40, Revenue from Contracts with Customers, Principal Agent Considerations, in determining the gross versus net revenue presentations for our performance obligations in the contract with a client. Revenue recorded where we act in the capacity of a principal is reported on a gross basis equal to the full amount of consideration to which we expect in exchange for the good or service transferred. Revenue recorded where we act in the capacity of an agent is reported on a net basis, exclusive of any consideration provided to the principal party in the transaction.
The principal versus agent evaluation is a matter of judgment that depends on the facts and circumstances of the arrangement and is dependent on whether we control the good or service before it is transferred to the client or whether we are acting as an agent of a third party. This evaluation is performed separately for each performance obligation identified. For the majority of our contracts, we are considered the principal in the transaction with the client and recognize revenue gross of any related channel partner fees or costs. We have certain agency arrangements where third parties control the goods or services provided to a client and we recognize revenue net of any fees owed to these third parties.
Payment terms and conditions vary by contract type, although our standard payment terms generally require payment within
30
to
60
days. In instances where the timing of revenue recognition differs from the timing of payment, we have determined our contracts do not generally include a significant financing component. The primary purpose of our invoicing terms is to provide clients with simplified and predictable ways of purchasing our products and services, not to receive financing from our clients or to provide clients with financing.
Contract Costs
Incremental Costs of Obtaining a Contract
Incremental costs of obtaining a contract primarily include commissions paid to our internal sales personnel. We consider all such commissions to be both incremental and recoverable since they are only paid when a contract is secured. These capitalized costs are amortized on a straight-line basis over the expected period of benefit, which is determined based on the average customer life, which includes anticipated renewals of contracts. As of September 30, 2025 and December 31, 2024, the total unamortized costs reported as deferred costs on our balance sheet amounted to $
30.8
million and $
29.0
million, respectively, for internal sales commissions. For the three months ended September 30, 2025 and 2024, amortization related to the sales commission asset was $
3.3
million and $
2.8
million, respectively. For the nine months ended September 30, 2025 and 2024, amortization related to the sales commission asset was $
9.6
million and $
7.8
million, respectively. The aforementioned amortization amounts are included in sales and marketing in our consolidated statements of operations.
Costs to Fulfill a Contract
We capitalize costs incurred to fulfill contracts that i) relate directly to the contract, ii) are expected to generate resources that will be used to satisfy performance obligations under the contract, and iii) are expected to be recovered through revenue generated under the contract. Costs incurred to implement clients on our solutions (e.g., direct labor) are capitalized and amortized on a straight-line basis over the estimated customer life if we expect to recover those costs. As of September 30, 2025 and December 31, 2024, the total unamortized costs reported as deferred costs on our balance sheet amounted to $
59.3
million and $
53.8
million, respectively, for fulfillment costs. For the three months ended September 30, 2025 and 2024, amortization related to the fulfillment cost asset was $
4.2
million and $
3.2
million, respectively. For the nine months ended September 30, 2025 and 2024, amortization related to the fulfillment cost asset was $
11.8
million and
Notes to Unaudited Condensed Consolidated Financial Statements
$
8.9
million, respectively. The aforementioned amortization amounts are included in the costs of revenue in our consolidated statements of operations.
There were
no
impairment losses relating to deferred costs during the periods presented.
Channel Partners
We account for fees paid to channel partners within sales and marketing expenses in the accompanying statements of operations. For the three months ended September 30, 2025 and 2024, we recorded fees to all channel partners of $
19.8
million and $
17.0
million, respectively. For the nine months ended September 30, 2025 and 2024, we recorded fees to all channel partners of $
57.1
million and $
47.6
million, respectively. As we are primarily responsible for contracting with and fulfilling contracts for the end user, we record revenue gross of related channel partner fees.
Cash and cash equivalents
We consider highly liquid investments with an original maturity of three months or less to be cash equivalents. We maintain our cash in bank deposit accounts, which, at times, may exceed federally insured limits. We have not experienced any credit losses in such accounts.
Investment securities
Our short-term investments, which consist of debt securities, are stated at fair value. These debt securities have been categorized as available-for-sale and classified as current assets given their maturity date is twelve months or less. Unrealized holding gains and losses for debt securities, net of applicable deferred taxes, are included in other comprehensive income or loss as a component of stockholders’ equity until realized from a sale or an expected credit loss is recognized. For the purpose of determining realized gross gains and losses for debt securities sold, that are included as a component of interest income/(expense) in the consolidated statements of income, the cost of investment securities sold is based upon specific identification. We recorded $
1.4
million and $
2.0
million of interest income on investment securities for the three and nine months ended September 30, 2025, within “Other expense” of our statements of operations. For the period ended September 30, 2025 we had purchases of short-term investments of $
206.4
million that were liquidated in the same period to help fund the acquisition of Iodine Software Holdings, Inc. (“Iodine”). No material gain or loss was recognized in the sale of these short-term investments.
Under the current expected credit losses model expected losses on available for sale debt securities are recognized through an allowance for credit losses rather than as reductions in the amortized cost of securities. For debt securities whose fair value is less than their amortized cost which we do not intend to sell or are not required to sell, we evaluate the expected cash flows to be received as compared to amortized cost and determine if an expected credit loss has occurred. In the event of any expected credit loss, only the amount of impairment associated with the expected credit loss is recognized in income with the remainder, if any, of the loss recognized in other comprehensive income. To the extent we have the intent to sell the debt security, or it is more likely than not we will be required to sell the debt security before recovery of our amortized cost basis, we recognize an impairment loss in income in an amount equal to the full difference between the amortized cost basis and the fair value.
There were no impairment losses relating to our investment securities during the periods presented.
Recently Issued Accounting Pronouncements Not Yet Adopted
In December 2023, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2023-09, “Improvements to Income Tax Disclosures”, which requires disaggregated information about a reporting entity’s effective tax rate reconciliation as well as information on income taxes paid. The standard is intended to benefit investors by providing more detailed income tax disclosures that would be useful in making capital allocation decisions. For public business entities, the ASU will be effective for annual periods beginning after December 15, 2024. The guidance will be applied on a prospective basis with the option to apply the standard retrospectively. Early adoption is permitted. We are
Notes to Unaudited Condensed Consolidated Financial Statements
currently evaluating the effect of the adoption of this amendment on our consolidated and condensed consolidated financial statements.
In November 2024, the FASB issued ASU 2024-13, “Expense Disaggregation Disclosures.” The standard is intended to benefit investors by providing more detailed information about expenses that is critically important in understanding an entity’s performance, assessing an entity’s prospects for future cash flows, and comparing an entity’s performance over time and with that of other entities. For public business entities, this ASU will be effective for annual reporting periods beginning after December 15, 2026, and interim reporting periods beginning after December 15, 2027. Early adoption is permitted. The amendments in this Update should be applied either (1) prospectively to financial statements issued for reporting periods after the effective date of this Update or (2) retrospectively to any or all prior periods presented in the financial statements. We are currently evaluating the effect of the adoption of this amendment on our consolidated financial statements.
In September 2025, the FASB issued ASU 2025-06, “Targeted Improvements to the Accounting for Internal-Use Software” to modernize the accounting guidance for the costs to develop software for internal use. The new guidance amends the existing standard that refers to various stages of a software development project to align better with current software development methods, such as agile programming. The new guidance will be effective for all entities for annual periods beginning after December 15, 2027. The guidance can be applied on a fully prospective basis, a modified basis for in-process projects, or a full retrospective basis. We are currently evaluating the effect of the adoption of this amendment on our consolidated financial statements.
3.
Revenue Recognition
Disaggregation of Revenue
The following table presents revenues disaggregated by revenue type and the timing of revenue recognition (in thousands):
Three months ended September 30,
Nine months ended September 30,
Recognition
2025
2024
2025
2024
Subscription revenue
Over time
$
134,450
$
117,993
$
390,599
$
336,421
Volume-based revenue
Over time
132,342
120,678
400,551
358,723
Implementation services and other revenue
Various
1,859
1,441
4,590
4,303
Total revenues
$
268,651
$
240,112
$
795,740
$
699,447
Contract Liabilities
We derive our revenue from contracts with clients primarily through subscription fees and volume-based fees. Our payment terms with the client generally comprise an initial payment for implementation services, which includes client enrollment and the setup of contracted solutions on our platform. These implementation fees are due upon contract execution. Additionally, subscription fees are earned on an ongoing basis, which are invoiced monthly.
Client payments received in advance of fulfilling the corresponding performance obligations are recorded as contract liabilities. Implementation fees are recognized over the customer life, with any unrecognized amounts deferred as contract liabilities. These amounts are reported as deferred revenue on our consolidated balance sheet.
Revenue recognized from amounts included in deferred revenue as of the beginning of the period was $
0.8
million and $
0.7
million for the three months ended September 30, 2025 and 2024, respectively. Revenue recognized from the amounts included in deferred revenue as of the beginning of the period was $
9.1
million and $
10.2
million for the nine months ended September 30, 2025 and 2024, respectively.
Notes to Unaudited Condensed Consolidated Financial Statements
Transaction Price Allocated to Remaining Performance Obligations
At September 30, 2025, the transaction price related to unsatisfied performance obligations that are expected to be recognized for the next
12
months and greater than
12
months was $
60.4
million and $
15.0
million, respectively.
The transaction price allocated to performance obligations that are unsatisfied (or partially unsatisfied) for executed contracts does not include revenue related to performance obligations that are part of a contract with an original expected duration of one year or less.
Additionally, the balance does not include variable consideration that is allocated entirely to wholly unsatisfied promises that form part of a single performance obligation composed of a series of distinct daily services.
Remaining performance obligation estimates are subject to change and are affected by several factors, including terminations and changes in the timing and scope of contracts, arising from contract modifications.
4.
Segments
Operating segments are defined as components of an enterprise about which separate financial information is evaluated regularly by the chief operating decision maker in deciding how to allocate resources and assessing performance. We have
one
business activity and there are no segment managers who are held accountable for operations, operating results and plans for products or components below the consolidated unit level. The geographical location of our customers has no impact on strategy or products offered. The “chief operating decision maker,” or CODM, assesses performance and allocates resources using a consolidated profitability metric as discussed below. Accordingly, we have determined that we operate in a single reportable operating segment.
Our CODM is our Chief Executive Officer. On a monthly basis, our CODM reviews the following financial information presented on a consolidated basis. The key profitability metric used for purposes of making key personnel staffing decisions, approving operating budgets and forecasts, and making strategy decisions is Net Income as detailed below. See Note 3 for our disaggregated revenue by type.
Notes to Unaudited Condensed Consolidated Financial Statements
5.
Fair Value Measurements and Disclosures
The following table presents the fair value hierarchy for financial assets and liabilities measured at fair value on a recurring basis (in thousands):
Balance Sheet Classification
Carrying Value
Level 1
Level 2
Level 3
September 30, 2025
Other financial assets:
Interest rate swaps
Other current assets
$
315
$
—
$
315
$
—
Other financial liabilities:
Interest rate swaps
Other accrued expenses
$
217
$
—
$
217
$
—
Interest rate swaps
Other long-term liabilities
$
815
$
—
$
815
$
—
December 31, 2024
Other financial assets:
Interest rate swaps
Other current assets
$
1,127
$
—
$
1,127
$
—
Interest rate swaps
Other long-term assets
$
22
$
—
$
22
$
—
The fair values of our interest rate swaps are based on the sum of all future net present value cash flows. The future cash flows are derived based on the terms of our interest rate swaps, as well as considering published discount factors, and projected SOFR curve. The fair value of long-term debt was determined using the present value of future cash flows based on the borrowing rates currently available for debt with similar terms and maturities. The carrying value of our first lien term loan facility was $
1,154.8
million and $
1,163.5
million compared to a fair value of $
1,151.9
million and $
1,169.4
million at September 30, 2025 and December 31, 2024, respectively. There were
no
transfers in or out of Level 3 during the periods presented.
As of September 30, 2025 and December 31, 2024, the carrying value of cash equivalents, accounts receivable, accounts payable, accrued liabilities, and other current assets and liabilities approximates fair value due to the short maturities of these instruments. Interest rate swaps are Level 2 instruments whose fair value is derived from discounted cash flows adjusted for nonperformance risk. Investment securities are Level 2 instruments whose fair value is observed through market data of similar securities. Money market funds are Level 1 instruments whose fair value is observed through daily quoted prices of similar assets. Money market funds are considered cash equivalents because they have a maturity of less than three months and are highly liquid.
6.
Property and Equipment, Net
The balances of the major classes of property and equipment are as follows (in thousands):
Notes to Unaudited Condensed Consolidated Financial Statements
Depreciation of fixed assets, including the amortization of capitalized software, for the three months ended September 30, 2025 and 2024 was $
5.4
million and $
21.1
million, respectively. Depreciation of fixed assets, including the amortization of capitalized software, for the nine months ended September 30, 2025 and 2024 was $
16.0
million and $
31.4
million, respectively.
We capitalized $
4.6
million and $
13.5
million in software development costs for the three and nine months ended September 30, 2025, respectively. We capitalized $
4.3
million and $
12.1
million in software developments costs for the three and nine months ended September 30, 2024, respectively. Amortization of capitalized software was $
3.6
million and $
2.7
million for the three months ended September 30, 2025 and 2024, respectively, and was $
10.3
million and $
7.4
million for the nine months ended September 30, 2025 and 2024, respectively. The net book value of capitalized software development costs was $
32.8
million and $
29.6
million as of September 30, 2025 and December 31, 2024, respectively.
There were
no
impairments of property and equipment for the three and nine months ended September 30, 2025 and 2024, respectively.
7.
Goodwill and Other Intangible Assets
Goodwill has a balance of $
3,020.0
million as of both September 30, 2025 and December 31, 2024. There were
no
additions, disposals or impairments to goodwill during the three and nine months ended September 30, 2025 and 2024.
Amortization for definite-lived intangible assets is as follows (in thousands, except useful life):
Gross Carrying
Amount
Accumulated
Amortization
Net
Carrying
Value
Weighted-
Average
Remaining
Useful Life
As of September 30, 2025
Customer relationships
$
1,429,400
$
(
511,890
)
$
917,510
10.4
Purchased developed technology
44,100
(
22,837
)
21,263
4.3
Tradenames and trademarks
40,300
(
24,106
)
16,194
4.1
Total
$
1,513,800
$
(
558,833
)
$
954,967
As of December 31, 2024
Customer relationships
$
1,429,400
$
(
440,729
)
$
988,671
11.1
Purchased developed technology
81,800
(
50,875
)
30,925
4.2
Tradenames and trademarks
40,700
(
21,247
)
19,453
4.7
Total
$
1,551,900
$
(
512,851
)
$
1,039,049
Amortization expense was $
27.9
million and $
39.1
million for the three months ended September 30, 2025 and 2024, respectively and was $
84.1
million and $
117.2
million for the nine months ended September 30, 2025 and 2024, respectively. During the three and nine months ended September 30, 2025, gross carrying amount of definite-lived intangible assets decreased by $
38.1
million due to disposals of fully amortized assets.
Notes to Unaudited Condensed Consolidated Financial Statements
Supplemental balance sheet information related to leases as of September 30, 2025 and December 31, 2024 are as follows:
September 30, 2025
December 31, 2024
Weighted average remaining lease term (years):
Operating leases
3.8
4.1
Financing leases
8.3
9.1
Weighted average discount rate:
Operating leases
4.9
4.7
Financing leases
5.9
5.9
9.
Income Taxes
We recognized income tax expense of $
12.1
million and income tax benefit of $
3.3
million for the three months ended September 30, 2025 and 2024, respectively, based on the quarter-to-date pre-tax income. We recognized income tax expense of $
43.5
million and income tax benefit of $
17.4
million for the nine months ended September 30, 2025 and 2024, respectively, based on the year-to-date pre-tax income. The Company’s effective income tax rate was
28.3
% and
37.7
% for the three months ended September 30, 2025 and 2024, respectively. The Company’s effective income tax rate was
32.1
% and
31.3
% for the nine months ended September 30, 2025 and 2024, respectively. Differences in the effective tax rate and statutory federal income tax rate of
21
% are primarily driven by the impact of certain limitations on the deductibility of stock-based compensation recognized for financial reporting purposes as well as state income taxes and research and development credits claimed.
On July 4, 2025, H.R.1, the budget reconciliation bill known as the “One Big Beautiful Bill Act”, was signed into law in the U.S. This legislation includes significant changes to U.S. tax law impacting corporate tax rates, bonus depreciation, interest limitations under Internal Revenue Code Section 163(j), and the treatment of domestic research and development expenditures. Following the enactment of the OBBBA, the Company recognized the tax effects of the legislation in the interim period that included the enactment date, as required under ASC 740. The Company has evaluated the impact of the OBBBA on deferred tax assets and liabilities, including adjustments to valuation allowances, and has reflected these effects in the consolidated financial statements for the three and nine months ended September 30, 2025. The impacts of adopting the tax law change did not materially impact the net income tax expense or deferred tax balances.
10.
Accounts Receivable Securitization
As of September 30, 2025 and December 31, 2024, we had $
80.0
million and $
80.0
million, respectively, outstanding under a receivables financing agreement with a counterparty as the lender, which provides for a
three-year
receivables facility with a limit of $
80.0
million (the “Receivables Facility”). Pursuant to the Receivables Facility, we sell and/or contribute current and future receivables to Waystar RC, LLC as the Special Purpose Entity (“SPE”). The SPE, in turn, pledges its interests in the receivables to the counterparty, which either makes loans or issues letters of credit on behalf of the SPE. All receivables remain on our balance sheet as they continue to be the property of our consolidated entities under the securitization.
The interest rate under the Receivables Facility is
1.61
% per annum above the SOFR rate with a minimum base of
0
%. The SOFR is adjusted each
thirty-day
period to the thirty-day SOFR rate. Interest under the Receivables Facility is paid monthly in arrears. At September 30, 2025, the effective interest rate for the Receivables Facility is
5.74
%.
All principal under the Receivables Facility is due on October 31, 2026.
The Receivables Facility contains certain covenants which, among other things, require we maintain certain collection thresholds with respect to our accounts receivable. We were in compliance with all such debt covenants during the periods presented.
Notes to Unaudited Condensed Consolidated Financial Statements
11.
Debt
Debt instruments consist primarily of term notes, revolving lines of credit, and a Receivables Facility as follows (in thousands):
September 30,
December 31,
2025
2024
First lien term loan facility outstanding debt
$
1,154,795
$
1,163,545
Revolving credit facility
—
—
Receivables facility outstanding debt
80,000
80,000
Total outstanding debt
1,234,795
1,243,545
Unamortized debt issuance costs
(
8,933
)
(
11,255
)
Current portion of long-term debt
(
11,668
)
(
11,668
)
Total long-term debt, net
$
1,214,194
$
1,220,622
The maturity of long-term principal payments (excluding debt discount) at September 30, 2025 is as follows (in thousands):
2025
$
2,918
2026
91,668
2027
11,668
2028
11,668
2029
1,116,873
$
1,234,795
As of September 30, 2025 and December 31, 2024, there is
no
outstanding balance on our revolving credit facility. The interest rate under the revolving credit facility is
1.75
% per annum above the SOFR rate with a minimum base of
0.00
%. The SOFR is adjusted each
thirty-day
period to the thirty-day SOFR rate. At September 30, 2025, the effective interest rate for the revolving credit facility is
5.88
%.
On August 12, 2025, we executed the eleventh amendment on the First Lien Credit Agreement whereby the outstanding balance was repriced being an interest rate of
2.00
% per annum above the SOFR rate with a minimum base of
0.00
% ("August 2025 First Lien Repricing"). There was no change in the outstanding loan balance before repricing and after repricing and the maturity date was not impacted by the amendment. As part of the August 2025 First Lien Repricing, we recorded $
0.7
million in third-party fees that were expensed immediately, which were recorded in general and administrative expenses in our consolidated statements of operations. We recorded a loss on extinguishment of $
0.7
million for the three and nine months ended September 30, 2025 related to the August 2025 First Lien Repricing. The SOFR is adjusted each
thirty-day
period to the thirty-day SOFR rate. Interest under the First Lien Credit Facility is paid monthly in arrears. At September 30, 2025, the effective interest rate for First Lien Credit Facility is
6.34
%.
Principal on the First Lien Credit Facility is payable in
20
equal quarterly installments with the remaining balance to be paid on October 22, 2029. As of September 30, 2025, there are
16
payments remaining. The First Lien Credit Agreement contains certain covenants which, among other things, restrict our ability to incur additional indebtedness. We were in compliance with such debt covenants as of September 30, 2025.
We had unamortized debt issuance costs of $
8.9
million and $
11.3
million as of September 30, 2025 and December 31, 2024, respectively.
In connection with the Revolving Credit Facility, unamortized debt issuance costs were $
1.6
million and $
2.1
million as of September 30, 2025 and December 31, 2024, respectively.
Notes to Unaudited Condensed Consolidated Financial Statements
12.
Derivative Financial Instruments
To mitigate the risk of a rise in interest rates on the First Lien Credit Facility, we entered into interest rate swaps on January 13, 2023, April 1, 2025 and April 9, 2025. We attempt to minimize our interest risk exposure by fixing our rate through the utilization of interest rate swaps, which are derivative instruments. The interest rate swaps mitigate the exposure on the variable component of interest on our First Lien Credit Facility. The interest rate swaps result in the fixed interest rate shown in the table below on the swapped portion of the First Lien Credit Facility. Our swaps are entered into with financial institutions that participate in the First Lien Credit Facility. By using a derivative instrument to hedge exposures to changes in interest rates, we expose ourselves to credit risk due to the possible failure of the counterparty to perform under the terms of the derivative contract.
As of September 30, 2025 and December 31, 2024, we have the following interest rate swap agreements designated as a hedging instruments:
Effective Dates
Floating Rate Debt
Fixed Rates
January 31, 2023 through January 31, 2026
$
506.7
million
3.87
%
April 1, 2025 through January 30, 2026
80.0
million
3.59
%
January 31, 2026 through March 31, 2027
275.0
million
3.59
%
January 31, 2026 through March 31, 2027
275.0
million
3.27
%
The gain or loss on the swaps is recognized in accumulated other comprehensive income/(loss) and reclassified into earnings as adjustments to interest expense in the same period or periods during which the swaps affect earnings. Gains or losses on the swaps representing hedge components excluded from the assessment of effectiveness are recognized in current earnings.
The effect of derivative instruments designated as hedging instruments on the accompanying consolidated financial statements is as follows (in thousands):
Derivatives - Cash Flow Hedging Relationships
Amount of Gain or
(Loss) Recognized
in AOCI/AOCL on
Derivative
Location of Gain or
(Loss) Reclassified
from AOCI/AOCL
into Income
Amount of Gain or
(Loss) Reclassified
from AOCI/AOCL
into Income
Total Interest
Expense on
Consolidated
Statements of
Operations
Interest rate swaps:
Three months Ended September 30, 2025
$
(
135
)
Interest expense
$
736
$
(
17,515
)
Three months Ended September 30, 2024
$
(
10,934
)
Interest expense
$
8,788
$
(
18,459
)
Nine Months Ended September 30, 2025
$
(
1,423
)
Interest expense
$
2,026
$
(
54,670
)
Nine Months Ended September 30, 2024
$
(
15,610
)
Interest expense
$
26,085
$
(
126,184
)
The net amount of accumulated other comprehensive income expected to be reclassified to interest income in the next twelve months is $
0.1
million.
13.
Related Party Transactions
At September 30, 2025 and December 31, 2024, we had $
56.4
million and $
35.6
million, respectively, of outstanding debt as part of the First Lien Credit Facility from Bain Affiliated Funds and CPPIB Credit Investments III Inc., affiliates of Bain Capital LP and Canada Pension Plan Investment Board (“Affiliated Debtholders”). Interest expense associated with and
Notes to Unaudited Condensed Consolidated Financial Statements
paid to Affiliated Debtholders was $
0.9
million and $
0.7
million for the three months ended September 30, 2025 and 2024, respectively and $
2.5
million and $
3.4
million for the nine months ended September 30, 2025 and 2024, respectively.
CPPIB has an ownership interest in us and a significant interest in the landlord that leases us office space under an operating lease agreement in Houston, Texas. For the three months ended September 30, 2025 and 2024, we expensed
zero
and $
0.1
million, respectively, and for the nine months ended September 30, 2025 and 2024, we expensed
zero
and $
0.2
million, respectively, for this office space lease in general and administrative expense.
Bain Capital LP has an ownership interest in us and a significant interest in some clients for whom we provide software solutions. For the three months ended September 30, 2025 and 2024, we earned revenue of $
0.8
million from
five
clients and $
0.4
million from
four
clients, respectively. For the nine months ended September 30, 2025 and 2024, we earned revenue of $
1.9
million from
five
clients and $
1.2
million from
four
clients, respectively. They also have an ownership interest in us and a significant interest in
two
vendors that provide us with software solutions. For the three months ended September 30, 2025 and 2024, we expensed $
0.6
million and $
0.1
million, respectively, and for the nine months ended September 30, 2025 and 2024, we expensed $
1.8
million and $
0.3
million for software services from these vendors in cost of revenue expense.
14.
Common and Preferred Stock
In connection with our initial public offering ("IPO"), the Company’s amended and restated certificate of incorporation became effective on June 10, 2024, which authorizes the issuance of
2,500,000,000
shares of common stock, par value $
0.01
per share, and
100,000,000
shares of preferred stock, par value $
0.01
per share. The shares of preferred stock have rights and preferences, including voting rights, designated from time to time by the Board of Directors. In connection with the amendment and restatement of the Company’s certificate of incorporation effective on the IPO date, the Class A common stock shares were automatically reclassified as, and became,
one
share of common stock. There were
174,667,840
and
172,108,240
common stock shares issued and outstanding as of September 30, 2025 and December 31, 2024, respectively.
15.
Retirement Plans
We maintain qualified 401(k) plans which cover substantially all employees meeting certain eligibility requirements. Participants may contribute a portion of their compensation to the plans, up to the maximum amount permitted under Section 401(k) of the Internal Revenue Code. Under these plans, we contribute various percentages of employees’ salaries to the plans. Total expenses included in operating expenses in the accompanying consolidated statement of operations related to the plans were $
1.3
million and $
1.1
million for the three months ended September 30, 2025 and 2024 and $
3.9
million and $
3.6
million for the nine months ended September 30, 2025 and 2024, respectively.
16.
Stock-based Compensation
Equity incentive plans
On October 22, 2019, the Board of Directors approved the Waystar Holding Corp. 2019 Stock Incentive Plan (“2019 Waystar Holding Plan”). Under this plan, we can issue up to
9.9
million options or other equity awards. The granted awards contain service criteria, performance criteria, market conditions, or a combination thereof for vesting and have a
10
-year contractual term. Options with a service condition generally vest over
5
years with
20
% vesting in equal vesting installments. Options with a performance condition and a market condition vest based upon a change in control, initial public offering, or a sponsor distribution or deemed return if the investors have achieved specified levels of return on investment. In addition, as part of a change in control in 2019,
2.2
million fully vested rollover options remain outstanding.
The Board of Directors approved the Waystar Holding Corp. 2024 Equity Incentive Plan (the “2024 Equity Incentive Plan”), effective as of June 6, 2024, the date of pricing of our IPO. Under this plan, we can issue non-qualified stock options, incentive stock options, stock appreciation rights, restricted shares of the Company’s Common Stock, restricted stock units, performance based stock units, and other equity-based awards tied to the value of the Company’s shares. Under this plan, we can issue up to
10
million options and other equity awards, subject to annual increases as outlined under the plan. The number of shares available to be issued automatically increases on the first day of each fiscal year beginning in 2025 by a number of shares equal to the lesser of the positive difference, if any, between
5
% of the outstanding common
Notes to Unaudited Condensed Consolidated Financial Statements
stock on the last day of the immediately preceding fiscal year, minus the plan share reserve on the last day of the immediately preceding fiscal year or such lesser number of shares as may be determined by the Board of Directors. Options with a service condition generally vest over
5
years with
20
% vesting in equal vesting installments. The restricted stock units (“RSUs”) under the 2024 Equity Incentive Plan generally vest over
4
or
5
years with
25
% or
20
% vesting, respectively, in equal vesting installments.
The performance-based stock units (“PSUs”) under the 2024 Equity Incentive Plan vest between
0
% and
200
% based on the company's total shareholder return (
“
TSR”) relative to a designated peer group as defined in the respective agreement over a
four-year
performance period.
As of September 30, 2025,
5.4
million shares were available for future grants under this plan.
The Board of Directors approved the Waystar Holding Corp. 2024 Employee Stock Purchase Plan (the “ESPP”), effective as of June 6, 2024, the date of pricing of our IPO. A total of
3,250,000
shares of common stock are initially reserved for the ESPP. The number of shares available to be issued for the ESPP will automatically increase each fiscal year beginning in 2025 by a number of shares equal to the lesser of the positive difference, if any, between
1
% of the outstanding common stock on the last day of the immediately preceding fiscal year and the number of shares of common stock available for the issuance of shares pursuant to the plan on the last day of the immediately preceding fiscal year or such lesser number of shares as may be determined by the Board of Directors. The number of shares available to be issued for the ESPP will not exceed
27,000,000
as outlined in the plan agreement. Our employees contribute funds via payroll deductions during the offering periods, which are used to buy Waystar common shares at a discount of up to
15
% of the purchase price at the purchase date. Offerings to purchase shares are granted twice annually on or about June 30 and December 31. During the three and nine months ended September 30, 2025,
37,323
of common shares have been issued as part of the ESPP. For the three and nine months ended September 30, 2025, expense of $
0.1
million and $
0.4
million, respectively, has been recorded which represents the
15
% discount given to the employees under the ESPP. During the three and nine months ended September 30, 2024,
zero
expense was recorded related to the
15
% discount given to the employees under the ESPP.
Stock Options
We utilize the Black-Scholes option pricing model to estimate the fair value of the service condition options under all plans and the Monte Carlo pricing model to estimate the fair value of the performance condition options under the 2019 Waystar Holding Corp. Plan. We value both types of options at the grant date using the following assumptions:
•
Risk-free interest rate—reflects the average rate on the United States Treasury bond with maturity equal to the expected term of the option;
•
Expected dividend yield—as we do not currently pay dividends or expect to pay dividends in the near future, the expected dividend yield is
zero
;
•
Expected term of stock award – under the 2024 Equity Incentive Plan, we utilized the simplified method due to the lack of historical experience activity for Waystar. The simplified method calculates the expected term as the mid-point between the vesting date and the contractual expiration date of the award. Under the 2019 Waystar Holding Corp. Plan, it is based on historical experience that is modified based on expected future changes;
•
Expected volatility in stock price—reflects the historical volatility of comparable public companies over the expected term of the stock option.
The weighted average grant date fair value of options granted during the nine months ended September 30, 2025 was $
18.69
per share.
No
options were granted during the three months ended September 30, 2025. The weighted average grant date fair value of options granted during the nine months ended September 30, 2024 was $
12.89
per share.
No
options were granted during the three months ended September 30, 2024. As of September 30, 2025, we had
6.8
million fully vested options with a weighted average exercise price of $
15.03
per share, an aggregate intrinsic value of $
156.3
million and an average remaining contractual term of
4.2
years. The total fair value of options vested for the three months ended September 30, 2025 and 2024 were $
2.9
million and $
2.9
million, respectively and $
16.5
million and $
4.8
million for the nine months ended September 30, 2025 and 2024, respectively.
Notes to Unaudited Condensed Consolidated Financial Statements
Information pertaining to option activity under all plans (including rollover options) during the nine months ended September 30, 2025 and 2024 is as follows:
Number of
options
Weighted average
exercise price per
share
Weighted
average
remaining
contractual life
Outstanding December 31, 2024
16,511,128
$
17.57
5.8
Granted
132,065
36.94
Exercised
(
2,061,626
)
10.14
Forfeited
(
121,202
)
29.75
Outstanding September 30, 2025
14,460,365
$
18.71
5.2
Number of
options
Weighted average
exercise price per
share
Weighted
average
remaining
contractual life
Outstanding December 31, 2023
13,032,541
$
15.20
5.7
Granted
4,003,703
24.20
Exercised
(
369,905
)
4.27
Forfeited
(
90,145
)
20.39
Outstanding September 30, 2024
16,576,194
$
17.59
6.1
The following is a summary of the significant assumptions used in estimating the fair value of options granted the three and nine months ended September 30, 2025 and 2024:
Three months ended September 30,
Nine months ended September 30,
2025
2024
2025
2024
Risk free interest rate
N/A
N/A
3.95
%
3.76
%-
4.59
%
Expected dividend yield
N/A
N/A
0
%
0
%
Expected term of stock award
N/A
N/A
6.2
5.0
-
6.5
Expected volatility in stock price
N/A
N/A
46.24
%
49.62
%-
51.89
%
The aggregate intrinsic value of options exercised (the difference between the fair market value of our stock on the date of exercise and the exercise price) was approximately $
12.8
million and $
6.7
million for the three months ended September 30, 2025 and 2024, respectively and $
61.7
million and $
6.7
million for the nine months ended September 30, 2025 and 2024, respectively.
We expect to incur compensation expense of approximately $
41.0
million over a weighted average of
3.4
years for all unvested time-based awards outstanding on September 30, 2025.
RSUs
The RSUs granted on June 10, 2024 in conjunction with the IPO were valued at the IPO price. Subsequent RSU grants have been valued using our common stock price as of the grant date based on the publicly traded value per NASDAQ, and are expensed on a straight-line basis over the applicable vesting period. All vesting is contingent on continued service.
Notes to Unaudited Condensed Consolidated Financial Statements
The following table summarizes RSU activity during the nine months ended September 30, 2025 and 2024.
Number of
shares
Weighted
average grant
date fair value
Outstanding December 31, 2024
2,089,241
$
21.91
Granted
2,323,495
37.34
Vested
(
460,362
)
21.50
Forfeited
(
55,819
)
27.40
Outstanding September 30, 2025
3,896,555
$
31.08
Number of
shares
Weighted
average grant
date fair value
Outstanding December 31, 2023
—
$
—
Granted
2,011,651
21.50
Vested
—
—
Forfeited
(
8,259
)
21.50
Outstanding September 30, 2024
2,003,392
$
21.50
We expect to incur compensation expense of $
110.8
million over a weighted average of
4.5
years for all unvested RSUs outstanding on September 30, 2025.
PSUs
We utilize the Monte Carlo pricing model to estimate the fair value of the market-based condition PSUs at the grant date under the 2024 Equity Incentive Plan. The Monte Carlo model incorporates assumptions regarding expected volatility, correlation between performance of our stock price and that of publicly traded peer companies, expected dividend yields and the risk-free interest rate. The Monte Carlo pricing model simulates potential future stock price paths yielding a grant date fair value that reflects the likelihood of varying outcomes. These awards are expensed on a straight-line basis over the applicable vesting period utilizing the fair value at the grant date.
The following is a summary of the significant assumptions used in estimating the fair value of PSUs granted during the nine months ended September 30, 2025. There were
no
PSUs granted during the three months ended September 30, 2025 or during the three and nine months ended September 30, 2024.
Notes to Unaudited Condensed Consolidated Financial Statements
The following table summarizes PSU activity during the nine months ended September 30, 2025.
Number of
shares
Weighted
average grant
date fair value
Outstanding December 31, 2024
—
$
—
Granted
396,197
61.67
Vested
—
—
Forfeited
—
—
Outstanding September 30, 2025
396,197
$
61.67
We expect to incur compensation expense of $
21.4
million over a weighted average of
3.5
years for all unvested PSUs outstanding on September 30, 2025.
Stock-based Compensation
We recorded $
11.6
million and $
7.9
million of stock-based compensation expense for the three months ended September 30, 2025 and 2024, respectively and $
29.9
million and $
47.4
million for the nine months ended September 30, 2025 and 2024, respectively.
Stock-based compensation expense was recorded in the following cost and expense categories in the consolidated statements of operations:
Three months ended September 30,
Nine months ended September 30,
2025
2024
2025
2024
Cost of revenue
$
418
$
300
$
1,064
$
2,161
General and administrative
7,218
4,832
18,418
27,043
Sales and marketing
2,392
1,587
6,198
10,958
Research and development
1,569
1,184
4,191
7,238
Total
$
11,597
$
7,903
$
29,871
$
47,400
17.
Other Accrued Expenses
Other accrued expenses consist of the following (in thousands):
Notes to Unaudited Condensed Consolidated Financial Statements
18.
Income/(Loss) Per Share
A reconciliation of the numerators and the denominators of the basic and diluted per share computations are as follows (in thousands, except for share and per share data):
Three months ended September 30,
Nine months ended September 30,
2025
2024
2025
2024
Basic income/(loss) per share:
Net income/(loss)
$
30,648
$
5,413
$
92,101
$
(
38,204
)
Net income/(loss) attributable to common shares
$
30,648
$
5,413
$
92,101
$
(
38,204
)
Weighted average common stock outstanding–(voting)
174,352,079
171,578,311
173,388,077
142,367,458
Basic weighted average common stock outstanding
174,352,079
171,578,311
173,388,077
142,367,458
Basic income/(loss) per share
$
0.18
$
0.03
$
0.53
$
(
0.27
)
Diluted income/(loss) per share:
Net income/(loss)
$
30,648
5,413
$
92,101
(
38,204
)
Net income/(loss) attributable to common shares
$
30,648
$
5,413
$
92,101
$
(
38,204
)
Dilutive effect of stock options – (voting)
6,048,579
4,268,993
6,736,352
—
Dilutive effect of RSUs – (voting)
836,036
334,207
1,040,195
—
Dilutive effect of ESPP – (voting)
3,339
—
1,113
—
Weighted average common stock outstanding–(voting)
181,240,033
176,181,511
181,165,737
142,367,458
Diluted weighted average common stock outstanding
181,240,033
176,181,511
181,165,738
142,367,458
Diluted income/(loss) per share
$
0.17
$
0.03
$
0.51
$
(
0.27
)
Because of their anti-dilutive effect,
1,652,397
and
5,247,024
common share equivalents comprised of stock options and RSUs have been excluded from the diluted earnings per share calculation for the three months ended September 30, 2025 and 2024, respectively. Additionally because of their anti-dilutive effect,
1,305,855
and
12,148,217
common share equivalents comprised of stock options and RSUs have been excluded from diluted earnings per share calculation for the nine months ended September 30, 2025 and 2024, respectively.
19.
Commitments and Contingencies
We may be subject to legal proceedings, claims, asserted or unasserted, and litigation arising in the ordinary course of business. We do not, however, currently expect that the ultimate costs to resolve any pending matter will have a material effect on our consolidated financial position, results of operations, or cash flows.
20.
Subsequent Events
We have evaluated subsequent events through the date of issuance.
On October 1, 2025, the Company completed the acquisition of Iodine pursuant to the Agreement and Plan of Merger (the "Merger Agreement") entered into on July 23, 2025 for total cash consideration of approximately $
458.6
million and
16,639,920
shares of common stock having a value of $
37.31
per share as outlined in the Merger Agreement. Due to the timing of the acquisition, the accounting conclusions related to the transaction have not yet been finalized.
On October 1, 2025, we entered into the Twelfth Amendment to the First Lien Credit Agreement to increase our First Lien Credit Facility by $
250.0
million, increase the maximum borrowing capacity under the revolving credit facility from $
400.0
million to $
500.0
million, and decrease the interest rate under the revolving credit facility from
1.75
% per annum above SOFR to
1.50
% per annum above SOFR. We drew $
30.0
million on the revolving credit facility to help fund the Iodine acquisition.
Notes to Unaudited Condensed Consolidated Financial Statements
On October 28, 2025, we reached a settlement agreement to terminate the prior lease on
one
of our office locations that was relocated in the third quarter of 2024. The total settlement was $
15.0
million. Due to the timing of the settlement, the accounting conclusions related to the transaction have not yet been finalized.
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations
The following discussion and analysis of Waystar Holding Corp. (“Waystar”, the “Company”, “we”, “us”, and “our”) financial condition and results of operations should be read in conjunction with our unaudited consolidated financial statements and the related notes included elsewhere in this Form 10-Q, and the consolidated financial statements and related notes included in the 2024 Form 10-K. In addition to historical information, this discussion and analysis contains forward-looking statements based on current expectations that involve risks, uncertainties, and other factors outside the Company’s control, as well as assumptions, such as our plans, objectives, expectations, and intentions. Our actual results may differ materially from those expressed or implied in the forward-looking statements as a result of various factors, including those described under the sections entitled “Cautionary Statement Concerning Forward-Looking Statements” above and “Risk Factors” in the 2024 Form 10-K and our other filings with the SEC.
Overview
Waystar provides healthcare organizations with mission-critical cloud software that simplifies healthcare payments. Our enterprise-grade platform streamlines the complex and disparate processes our healthcare provider clients must manage to be reimbursed correctly, while improving the payments experience for providers, patients, and payers. We leverage AI as well as proprietary, advanced algorithms to automate payment-related workflow tasks and drive continuous improvement, which enhances claim and billing accuracy, enriches data integrity, and reduces labor costs for providers.
Our software is used daily by providers of all types and sizes across the continuum of care, including physician practices, clinics, surgical centers, and laboratories, as well as large hospitals and health systems. We currently serve over 30,000 clients of various sizes, representing over one million distinct providers practicing across a variety of care sites, including 17 of the top 20 U.S. News Best Hospitals. Our business model is designed such that as our clients grow to serve more patients, their claims and transactional volumes increase, resulting in corresponding growth in our business. In addition, our clients frequently adopt a greater number of our solutions over time and introduce our solutions across new sites of care. In 2024, we facilitated over six billion healthcare payments transactions, including over $1.8 trillion in gross claims volume. As of 2024, we facilitated healthcare payments transactions spanning approximately 50% of patients in the United States.
Our platform benefits from powerful network effects. Our cloud-based software is driven by a sophisticated, automated, and curated rules engine, employing AI to generate and incorporate real-time feedback from millions of network transactions processed through our platform each day. Every transaction we process provides additional data insights across providers, patients, and payers, which are embedded in updates that are deployed efficiently across our client base. This results in cumulative benefits to us over time —as we capture more data from each transaction we process, we leverage that data to continue to improve the Waystar platform through embedded machine learning, advanced algorithms, and other in-house AI technologies to deliver added value to our clients. In turn, the more value we create for our clients, the more likely it is that they will continue to use our products, allowing us to continue to capture more data that results in tangible improvements to our platform. As a result, our clients benefit from faster and more efficient performance from software that is evolving to meet ever-changing regulatory and payer requirements, enabling accurate and timely reimbursement.
We have demonstrated an ability to drive recurring, predictable, and profitable growth. Over 99% of our revenue is either recurring subscription or based on highly predictable volumes. For the twelve months ended September 30, 2025, our Net Revenue Retention Rate was 113.1% and we have 1,306 clients as of September 30, 2025 generating over $100,000 over the same twelve month period. For the nine months ended September 30, 2025, we generated revenue of $795.7 million (reflecting a 13.8% increase compared to revenue of $699.4 million for the same period in the prior year), net income of $92.1 million compared to net loss of $38.2 million for the same period in the prior year, and Adjusted EBITDA of $333.0 million (reflecting a 17.5% increase compared to Adjusted EBITDA of $283.3 million for the same period in the prior year).
Initial Public Offering
In June 2024, we completed an initial public offering (the “IPO”) of 45,000,000 shares of common stock at a price of $21.50 per share. After underwriting discounts and commissions of $53.2 million, we received total proceeds from the offering of $914.3 million. On July 5, 2024, pursuant to the option granted to the underwriters for a period of 30 days from the date of the IPO Prospectus to purchase up to 6,750,000 additional shares of common stock from us at the IPO price less the underwriting discount, the underwriters exercised the right to purchase 5,059,010 additional shares of common stock,
resulting in additional net proceeds of $102.8 million, after deducting underwriting discounts and commissions of $6.0 million. The remaining option to purchase additional shares expired unexercised at the end of the 30-day period. See Item 1, Financial Statements, Note 1 (Business) in the 2024 Form 10-K for more information.
Secondary Offerings
On February 24, 2025, the Institutional Investors closed an underwritten public offering of 23,000,000 shares of our common stock (inclusive of the underwriters’ option to purchase additional shares) (the “First Secondary Offering”). On May 15, 2025, the Institutional Investors closed another underwritten public offering of 14,375,000 shares of our common stock (inclusive of the underwriters' option to purchase additional shares) (the "Second Secondary Offering"). Additionally on September 10, 2025, the Institutional Investors closed another underwritten public offering of 18,000,000 shares of our common stock (the "Third Secondary Offering"). The Company did not sell any shares in these offerings or receive any proceeds from these offerings. Pursuant to the terms of the Amended and Restated Registration Rights Agreement, dated as of June 10, 2024, by and among the Company, the Institutional Investors, and certain other parties thereto, we paid $1.4 million and $4.6 million in certain expenses on behalf of the selling stockholders related to these offerings for the three and nine months ended September 30, 2025, respectively, while the selling stockholders paid all applicable underwriting discounts and commissions.
Iodine Acquisition
On July 23, 2025, we entered into the Merger Agreement to acquire Iodine through a series of mergers. Iodine is a trusted leader in AI-powered clinical intelligence, enhancing clinical documentation and accuracy, streamlining utilization management, and preventing revenue leakage before billing. This strategic move is expected to bolster our AI leadership, automate manual work, and improve financial performance for providers. The acquisition was completed on October 1, 2025 for a total purchase price of $1.25 billion. The consideration paid was approximately $458.6 million in cash consideration and 16,639,920 shares of common stock having a value of $37.31 per share, and certain adjustments as outlined in the Merger Agreement.
Significant Items Affecting Comparability
We believe that the future growth and profitability of our business, and the comparability of our results from period to period, depend on numerous factors, including the following:
Our Ability to Expand our Relationship with Existing Clients
As our clients grow their businesses and provide more services and see more patients, our volume-based revenues also increase. In addition, our growth in revenues also depends on our ability to sell more products and solutions to existing clients, including through cross-selling as our clients adopt additional Waystar offerings as well as up-selling as our clients leverage our solutions across additional providers and sites of care.
Our Ability to Grow our Client Base
We are focused on continuing to grow our client base, which will depend in part on our ability to continue to maintain our product leadership, invest in our research and development team, and maintain our reputation and brand.
Impacts of the IPO
•
Debt Repayment.
We used proceeds from our IPO to repay an aggregate of $1.0 billion in outstanding principal amount on our First Lien Credit Facility in the second and third quarters of fiscal 2024. This debt repayment has contributed to lower interest expense for the three and nine months ended September 30, 2025 compared to the same periods in the prior year.
•
Stock-Based Compensation Expenses.
We expect to recognize stock-based compensation expense of $17.9 million per year over the applicable vesting periods in connection with equity awards granted in connection with the IPO. Such stock-based compensation expense will be reflected in our results of operations from the closing date of the IPO through the applicable vesting periods of such awards. Additionally, we recognized $33.1 million of stock-based compensation expense during the nine months ended September 30, 2024, as the vesting of our performance
condition options became probable upon the closing of the IPO as the implicit service period for the awards established at the grant date had elapsed.
•
Incremental Public Company Expenses.
Following the IPO, we have incurred significant expenses on an ongoing basis that we did not incur as a private company. Those costs include additional director and officer liability insurance expenses, as well as third-party and internal resources related to accounting, auditing, Sarbanes-Oxley Act compliance, legal, and investor and public relation expenses. These costs are generally expensed under general and administrative expenses.
Components of Results of Operations
Revenue
We primarily generate two types of revenue: (i) subscription revenue and (ii) volume-based revenue, which account for 99% of total revenue for all periods presented. We believe we have high visibility into our volume-based and subscription revenue from existing clients. We refer to the solutions our clients use to better process and understand their payment workflows from payers as provider solutions, and we refer to the products that assist healthcare providers in collecting payments from patients as patient payment solutions. We expect provider solutions will continue to generate the substantial majority of our total revenue, although the revenue mix attributable to patient payment solutions is expected to increase slightly over time.
•
Subscription revenue
. Reflects recurring monthly provider count fees and minimum amounts owed. The vast majority of subscription revenue is generated by provider solutions, which constituted approximately 70% of total revenue in each of the three and nine months ended September 30, 2025 and 2024.
•
Volume-based revenue
. Represents recurring fees associated with transaction count or dollar volumes in excess of minimums. Generally, approximately half of our volume-based revenue is generated from provider solutions that are based on transaction count, with the other half from patient payments solutions that are based on either dollar volumes or transaction count.
We also derive revenue from implementation fees for our software, as well as hardware sales to facilitate patient payments. Our implementation fees are billed upfront and the revenue is recognized ratably over the customer's life.
Cost of Revenue (Exclusive of Depreciation and Amortization)
Cost of revenue includes salaries, stock-based compensation, and benefits (“personnel costs”) for our team members who are focused on implementation, support, and other client-focused operations, as well as team members focused on enhancing and developing our platform. Cost of revenue also includes costs for third-party technology such as interchange fees and infrastructure related to the operations of our platform, including communicating and processing patient payments, and services to support the delivery of our solutions. Third-party costs for patient payments solutions are approximately 60% of the revenue generated from these solutions, while third-party costs for provider solutions are approximately 6% to 8% of the associated revenue, in each case, for both the three and nine months ended September 30, 2025 and 2024.
Sales and Marketing
Sales and marketing costs consist primarily of personnel costs, internal sales commissions, channel partner fees, travel, and advertising costs.
General and Administrative
General and administrative expenses consist of personnel costs incurred in our corporate service functions such as finance expenses, legal, human resources, and information technology, as well as other professional service costs.
Research and Development
Research and development costs consist primarily of personnel costs for team members engaged in research and development activities as well as third-party fees. All such costs are expensed as incurred, except for capitalized software development costs.
Depreciation and amortization consists of the depreciation of property and equipment and amortization of certain intangible assets, including capitalized software.
Other Expense
Other expense consists primarily of interest expense and related-party interest expense, inclusive of the impact of interest rate swaps and net of interest income.
Income Tax Expense/(Benefit)
Income tax expense/(benefit) includes current income tax and income tax credits from deferred taxes. Income tax expense/benefit is recognized in profit and loss except to the extent that it relates to items recognized in equity or other comprehensive income, in which case the income tax expense/(benefit) is also recognized in equity or other comprehensive income.
Results of Operations for the Three Months Ended September 30, 2025 and 2024
The following table provides consolidated operating results for the periods indicated and percentage of revenue for each line item:
Three months ended September 30,
2025
2024
Change
($ in thousands)
($)
(%)
($)
(%)
($)
(%)
Revenue
$
268,651
100.0
%
$
240,112
100.0
%
$
28,539
11.9
%
Operating expenses
Cost of revenue (exclusive of depreciation and amortization)
Revenue was $268.7 million for the three months ended September 30, 2025 as compared to $240.1 million for the three months ended September 30, 2024, an increase of $28.5 million, or 11.9%, of which $16.5 million was attributed to subscription revenue from new and existing clients, almost all of which was generated by provider solutions. Another $11.7 million was attributed to volume-based revenue primarily related to expansion of existing client usa
ge, of which $5.7 million was generated by patient payments solutions and $5.9 million was generated by provider solutions.
Cost of Revenue (Exclusive of Depreciation and Amortization)
Cost of revenue was $85.1 million for the three months ended September 30, 2025 as compared to $80.5 million for the three months ended September 30, 2024, an increase of $4.6 million, or 5.7%. The increase was primarily driven by $2.1 million in increased costs stemming from higher transaction volumes and associated third-party costs, including higher platform usage of which approximately $4.6 million was third-party costs associated with payment solutions offset by a decrease of $2.4 million from third-party costs associated with provider solutions, primarily from timing of prior acquisition synergy attainment. Additionally, there was a $1.8 million of increased personnel costs, net of capitalization expense
.
Sales and Marketing
Sales and marketing expense was $45.2 million for the three months ended September 30, 2025 as compared to $38.5 million for the three months ended September 30, 2024, an increase of $6.7 million, or 17.4%. The increase was primarily driven by an increase in channel partner fees and amortization of the internal commission deferred contract costs asset of $3.3 million, increased personnel costs of $1.4 million and increased stock-based compensation costs of $0.8 million.
General and Administrative
General and administrative expense was $32.4 million for the three months ended September 30, 2025 as compared to $22.7 million for the three months ended September 30, 2024, an increase of $9.7 million, or 42.8%. The increase was primarily due to an increase in third party professional fees of $7.1 million from acquisition activity, the August 2025 Debt Repricing and secondary offerings during the quarter. Additionally, there was an increase in stock-based compensation expense of $2.4 million.
Research and Development
Research and development expense was $12.4 million for the three months ended September 30, 2025 as compared to $11.1 million for the three months ended September 30, 2024, an increase of $1.3 million, or 11.9%. The increase was primarily due to an increase in personnel costs of $0.8 million and an increase in stock-based compensation expense of $0.4 million.
Depreciation and Amortization
Depreciation and amortization expense was $33.3 million for the three months ended September 30, 2025, as compared to $60.2 million for the three months ended September 30, 2024, a decrease of $26.9 million, or 44.7%. The decrease was due to several intangible assets becoming fully amortized in the prior year, driving a decrease in intangible amortization.
Interest Expense
Total interest expense was $17.5 million for the three months ended September 30, 2025 as compared to $18.5 million for the three months ended September 30, 2024, a decrease of $0.9 million, or 5.1%.
The slight decrease was primarily attributable to debt repricings associated with the First Lien Credit Facility executed in December 2024 and August 2025 partially offset by a favorable interest rate swap that matured in October 2024.
Income Tax Expense/(Benefit)
Income tax expense was $12.1 million for the three months ended September 30, 2025, as compared to an income tax expense of $3.3 million for the three months ended September 30, 2024, an increase of $8.8 million. The increase was primarily driven by the increase in pre-tax income/(loss).
Results of Operations for the Nine Months Ended September 30, 2025 and 2024
The following table provides consolidated operating results for the periods indicated and percentage of revenue for each line item:
Nine months ended September 30,
2025
2024
Change
($ in thousands)
($)
(%)
($)
(%)
($)
(%)
Revenue
$
795,740
100.0
%
$
699,447
100.0
%
$
96,293
13.8
%
Operating expenses
Cost of revenue (exclusive of depreciation and amortization)
255,525
32.1
%
236,188
33.8
%
19,337
8.2
%
Sales and marketing
128,805
16.2
%
117,945
16.9
%
10,860
9.2
%
General and administrative
84,914
10.7
%
88,794
12.7
%
(3,880)
(4.4)
%
Research and development
36,103
4.5
%
37,303
5.3
%
(1,200)
(3.2)
%
Depreciation and amortization
100,106
12.6
%
148,635
21.3
%
(48,529)
(32.6)
%
Total operating expenses
605,453
76.1
%
`
628,865
89.9
%
(23,412)
(3.7)
%
Income from operations
190,287
23.9
%
70,582
10.1
%
119,705
169.6
%
Other expense
Interest expense
(52,195)
(6.6)
%
(122,759)
(17.6)
%
70,564
(57.5)
%
Related party interest expense
(2,475)
(0.3)
%
(3,425)
(0.5)
%
950
(27.7)
%
Income/(loss) before income taxes
135,617
17.0
%
(55,602)
(7.9)
%
191,219
(343.9)
%
Income tax expense/(benefit)
43,516
5.5
%
(17,398)
(2.5)
%
60,914
(350.1)
%
Net income/(loss)
$
92,101
11.6
%
$
(38,204)
(5.5)
%
$
130,305
(341.1)
%
Revenue
Nine months ended September 30,
2025
2024
Change
($ in thousands)
($)
(%)
($)
(%)
($)
(%)
Revenue
Subscription revenue
$
390,599
49.1
%
$
336,421
48.1
%
$
54,178
16.1
%
Volume-based revenue
400,551
50.3
%
358,723
51.3
%
41,828
11.7
%
Services and other revenue
4,590
0.6
%
4,303
0.6
%
287
6.7
%
Total Revenue
$
795,740
100.0
%
$
699,447
100.0
%
$
96,293
13.8
%
Revenue was $795.7 million for the nine months ended September 30, 2025 as compared to $699.4 million for the nine months ended September 30, 2024, an increase of $96.3 million, or 13.8%, of which $54.2 million was attributed to subscription revenue from new and existing clients, almost all of which is generated by provider solutions. Another $41.8 million was attributed to volume-based revenue primarily related to expansion of existing client usage, most of which was generated by patient payments solutions.
Cost of Revenue (Exclusive of Depreciation and Amortization)
Cost of revenue was $255.5 million for the nine months ended September 30, 2025 as compared to $236.2 million for the nine months ended September 30, 2024, an increase of $19.3 million, or 8.2%. The increase was primarily driven by $13.9 million in increased costs stemming from higher transaction volume and associated third-party costs, including higher platform usage, of which approximately $20.1 million was third-party costs associated with payment solutions offset by a decrease of $6.2 million from third-party costs associated with provider solutions, primarily from timing of prior acquisition synergy attainment. Additionally, there was an increase in personnel costs, net of capitalization expenses, of $5.8 million.
Sales and marketing expense was $128.8 million for the nine months ended September 30, 2025 as compared to $117.9 million for the nine months ended September 30, 2024, an increase of $10.9 million, or 9.2%
. Th
e increase was primarily driven by an increase in channel partner fees and amortization of the internal commission deferred contract costs asset of $11.3 million associated with revenue growth.
General and Administrative
General and administrative expense was $84.9 million for the nine months ended September 30, 2025 as compared to $88.8 million for the nine months ended September 30, 2024, a decrease of $3.9 million, or 4.4%. The decrease was primarily due to a reduction in stock-based compensation expense of $8.6 million attributable to the recognition of performance condition options that did not recur during the nine months ended September 30, 2025 (see “Impacts of IPO” section above) partially offset by an increase in personnel costs of $3.9 million.
Research and Development
Research and development expense was $36.1 million for the nine months ended September 30, 2025 as compared to $37.3 million for the nine months ended September 30, 2024, a decrease of $1.2 million, or 3.2%. The decrease was primarily driven by a decrease in stock-based compensation expense of $3.0 million attributable to the recognition of performance condition options that did not recur during the nine months ended September 30, 2025 (see “Impacts of IPO” section above) partially offset by an increase in personnel costs, net of capitalization expenses of $1.8 million.
Depreciation and Amortization
Depreciation and amortization expense was $100.1 million for the nine months ended September 30, 2025, as compared to $148.6 million for the nine months ended September 30, 2024, a decrease of $48.5 million, or 32.6%. The decrease was due to several intangible assets becoming fully amortized in the prior year, driving a decrease in intangible amortization.
Interest Expense
Total interest expense was $54.7 million for the nine months ended September 30, 2025 as compared to $126.2 million for the nine months ended September 30, 2024, a decrease of $71.5 million, or 56.7%.
The decrease was driven by the paydowns during 2024 totaling $1.0 billion on our First Lien Credit Facility decreasing the corresponding interest expense.
Income Tax Benefit
Income tax expense was $43.5 million for the nine months ended September 30, 2025 as compared to an income tax benefit of $17.4 million for the nine months ended September 30, 2024, an increase of $60.9 million. The increase was primarily driven by the increase in pre-tax income/(loss).
Non-GAAP Financial Measures
We present adjusted EBITDA, adjusted EBITDA margin, non-GAAP net income/(loss), and non-GAAP net income/(loss) per share as supplemental measures of financial performance that are not required by, or presented in accordance with, GAAP. We believe they assist investors and analysts in comparing our operating performance across reporting periods on a consistent basis by excluding items that we do not believe are indicative of our core operating performance. Management believes these non-GAAP financial measures are useful to investors in highlighting trends in our operating performance, while other measures can differ significantly depending on long-term strategic decisions regarding capital structure, the tax jurisdictions in which we operate, and capital investments. Management uses these to supplement GAAP measures of performance in the evaluation of the effectiveness of our business strategies, to make budgeting decisions, to establish discretionary annual incentive compensation, and to compare our performance against that of other peer companies using similar measures. Management supplements GAAP results with non-GAAP financial measures to provide a more complete understanding of the factors and trends affecting the business than GAAP results alone provide.
Adjusted EBITDA, adjusted EBITDA margin, non-GAAP net income/(loss), and non-GAAP net income/(loss) per share are not recognized terms under GAAP and should not be considered as an alternative to net income (loss) or net income (loss) margin as measures of financial performance or cash provided by operating activities as a measure of liquidity, or
any other performance measure derived in accordance with GAAP. Additionally, these measures are not intended to be a measure of free cash flow available for management’s discretionary use, as they do not consider certain cash requirements such as interest payments, tax payments, and debt service requirements. The presentations of these measures have limitations as analytical tools and should not be considered in isolation, or as a substitute for analysis of our results as reported under GAAP. Because not all companies use identical calculations, the presentations of these measures may not be comparable to other similarly titled measures of other companies and can differ significantly from company to company. A reconciliation is provided below for our non-GAAP financial measures to the most directly comparable financial measure stated in accordance with GAAP. Investors are encouraged to review the related GAAP financial measures and the reconciliation of non-GAAP financial measures to their most directly comparable GAAP financial measures, and not to rely on any single financial measure to evaluate our business.
Adjusted EBITDA and Adjusted EBITDA Margin
We define adjusted EBITDA as net income/(loss) before interest expense, net, income tax expense/(benefit), depreciation and amortization, and as further adjusted for stock-based compensation expense, acquisition and integration costs, asset and lease impairments, costs related to amended debt agreements, and costs related to our IPO and the Secondary Offerings. Adjusted EBITDA margin represents adjusted EBITDA as a percentage of revenue.
The following table presents a reconciliation of net income/(loss) to adjusted EBITDA and net income/(loss) margin to adjusted EBITDA margin for the three and nine months ended September 30, 2025 and 2024:
(a)
Adjustments relate to additional lease costs due to the relocation of our Louisville office totaling $0.2 million and $0.7 million, respectively, and executive severance totaling $0.0 million and $0.6 million, respectively, for the three and nine months ended September 30, 2025. For the three and nine months ended September 30, 2024, adjustments relate to additional lease costs due to the relocation of our Louisville office.
Non-GAAP Net Income/(Loss) and Non-GAAP Net Income/(Loss) Per Share
We define non-GAAP net income as GAAP net income/(loss) excluding the impact of stock-based compensation, acquisition and integration costs, asset and lease impairments, costs related to our IPO, and the Secondary Offerings, and costs related to amended debt agreements and amortization of intangibles. The tax effects of the adjustments are calculated using a management estimated annual effective non-GAAP tax rate of 21%, which is based on our statutory federal tax rate and provides consistency across interim reporting periods by eliminating the effects of non-recurring and period specific items. Due to the differences in the tax treatment of items excluded from non-GAAP net income, our estimated tax rate on non-GAAP net income may differ from our GAAP tax rate.
Non-GAAP net income per share is shown on both a basic and diluted basis and is defined as non-GAAP net income divided by the basic or diluted weighted-average shares, respectively.
The following table presents a reconciliation of net loss to non-GAAP net income/(loss) and non-GAAP net income/(loss) per share for the three and nine months ended September 30, 2025 and 2024:
Three months ended September 30,
Nine months ended September 30,
($ in thousands)
2025
2024
2025
2024
Net income/(loss)
$
30,648
$
5,413
$
92,101
$
(38,204)
Stock based compensation
11,597
7,903
29,871
47,400
Acquisition and integration costs
5,313
188
6,197
696
Costs related to amended debt agreements
649
106
649
12,876
IPO and Secondary Offering expenses
1,372
109
4,571
2,114
Other (a)
240
16,816
1,320
16,816
Intangible amortization
27,851
39,080
84,081
117,240
Tax effect of adjustments
(9,875)
(13,482)
(26,605)
(41,400)
Non-GAAP net income/(loss)
$
67,795
$
56,133
$
192,185
$
117,538
Non-GAAP net income/(loss) per share:
Basic
$
0.39
$
0.33
$
1.11
$
0.83
Diluted
$
0.37
$
0.32
$
1.06
$
0.80
Weighted-average shares outstanding:
Basic
174,352,079
171,578,311
173,388,077
142,367,458
Diluted
181,240,033
176,181,511
181,165,738
146,843,861
(a)
Adjustments relate to additional lease costs due to the relocation of our Louisville office totaling $0.2 million and $0.7 million, respectively, and executive severance totaling $0.0 million and $0.6 million, respectively, for the three and nine months ended September 30, 2025. For the three and nine months ended September 30, 2024, adjustments relate to additional lease costs due to the relocation of our Louisville office.
Key Performance Metrics
Net Revenue Retention Rate
We also regularly monitor and review our Net Revenue Retention Rate.
The following table presents our Net Revenue Retention Rate for September 30, 2025 and 2024, respectively:
Twelve months ended September 30,
($in thousands)
2025
2024
Net Revenue Retention Rate
113.1
%
109.4
%
Our Net Revenue Retention Rate compares twelve months of client invoices for our solutions at two period end dates. To calculate our Net Revenue Retention Rate, we first accumulate the total amount invoiced during the twelve months ending with the prior period-end, or Prior Period Invoices. We then calculate the total amount invoiced to those same clients for the twelve months ending with the current period-end, or Current Period Invoices. Current Period Invoices are inclusive of upsell, downsell, pricing changes, clients that cancel or chose not to renew, and discontinued solutions with continuing clients. The Net Revenue Retention Rate is then calculated by dividing the Current Period Invoices by the Prior Period Invoices. Our total invoices included in the analysis are greater than 98% of reported revenue. We use Net Revenue Retention Rate to evaluate our ongoing operations and for internal planning and forecasting purposes. Acquired businesses are included in the last-twelve month Net Revenue Retention Rate in the ninth quarter after acquisition, which is the earliest point that comparable post-acquisition invoices are available for both the current and prior twelve-month period.
Customer Count with >$100,000 Revenue
We also regularly monitor and review our count of clients who generate more than $100,000 of revenue.
The following table sets forth our count of clients who generate more than $100,000 of revenue for the periods presented:
Our count of clients who generate more than $100,000 of revenue is based on an accumulation of the amounts invoiced to clients over the preceding twelve months. The invoices for acquired clients are included starting in the first full calendar quarter after the date of acquisition.
Liquidity and Capital Resources
Overview
We assess our liquidity in terms of our ability to generate adequate amounts of cash to meet current and future needs. Our expected primary uses on a short-term and long-term basis are for working capital, capital expenditures, debt service requirements, and investments in future growth, including acquisitions. We have historically funded our operations and acquisitions through our cash and cash equivalents, cash flows from operations, and debt financings. We believe that our existing unrestricted cash on hand, expected future cash flows from operations, and additional borrowings will provide sufficient resources to fund our operating requirements, as well as future capital expenditures, debt service requirements, and investments in future growth for at least the next 12 months. To the extent additional funds are necessary to meet our long-term liquidity needs as we continue to execute our business strategy, we anticipate that they will be obtained through the incurrence of additional indebtedness, additional equity financings, or a combination of these potential sources of funds. In the event that we need access to additional cash, we may not be able to access the credit markets on commercially acceptable terms or at all. Our ability to fund future operating expenses and capital expenditures and our ability to meet future debt service obligations or refinance our indebtedness will depend on our future operating performance, which will be affected by general economic, financial, and other factors beyond our control, including those described under “Risk factors” in the 2024 Form 10-K.
On September 30, 2025 and December 31, 2024, we had restricted cash of $24.3 million and $22.4 million, respectively, which consists of cash deposited in lockbox accounts owned by us which are contractually required to be disbursed to participating clients on the following day, as well as cash collected on behalf of healthcare providers from patients that have not yet been remitted to providers. These funds payable are not available for our use and liquidity, and are offset on our balance sheet by an aggregated funds payable liability.
On October 1, 2025, we paid approximately $458.6 million in cash in respect of the cash component of the merger consideration for our acquisition of Iodine. On October 1, 2025, we also entered into the Twelfth Amendment to the First Lien Credit Agreement to increase our First Lien Credit Facility by $250.0 million, increase the maximum borrowing capacity under the revolving credit facility from $400.0 million to $500.0 million, and decrease the interest rate under the revolving credit facility from 1.75% per annum above SOFR to 1.50% per annum above SOFR. We drew $30.0 million on the revolving credit facility to help fund the Iodine acquisition.
Our liquidity is influenced by many factors, including timing of revenue and corresponding cash collections, the amount and timing of investments in strategic initiatives, our investments in property, equipment, and software, as well as other factors described under “Risk factors” in the 2024 Form 10-K. Depending on the severity and direct impact of these factors on us, we may not be able to secure additional financing on acceptable terms, or at all.
Cash Flows
Cash flows from operating, investing, and financing activities for the nine months ended September 30, 2025 and September 30, 2024, are summarized in the following table:
Cash flows provided by operating activities were $243.0 million for the nine months ended September 30, 2025 as compared to $105.0 million for the nine months ended September 30, 2024, an increase of $138.0 million
. This increase is largely driven by changes in working capital, increases in revenue and profits, and decreases in cash paid for interest due to multiple paydowns on our First Lien Credit Facility in 2024.
Cash Flows Used in Investing Activities
Cash flows used in investing activities were $17.1 million for the nine months ended September 30, 2025 as compared to $21.0 million for the nine months ended September 30, 2024 a decrease of cash used of $4.0 million. Cash flows used in investing activities decreased due t
o less purchases of property and equipment during the nine months ended September 30, 2025 compared to the nine months ended September 30, 2024.
Cash Flows Provided By Financing Activities
Cash flows provided by financing activities were $14.8 million for the nine months ended September 30, 2025 as compared to $15.0 million for the nine months ended September 30, 2024, a decrease of $0.2 million.
The net cash provided in 2024 was driven by proceeds from last year's IPO, net of underwriting discounts and the corresponding paydown on debt, as well as proceeds from the issuance of debt, net of creditor fees, during the nine months ended September 30, 2024. The net cash provided in 2025 was from proceeds from the exercise of stock options during the nine months ended September 30, 2025.
Indebtedness
Refer to Item 1, Financial Statements, Notes 11 (Accounts Receivable Securitization) and 12 (Debt), for a description of our Credit Facilities.
Critical Accounting Policies and Estimates
The above discussion and analysis of our financial condition and results of operations is based upon our consolidated financial statements. The preparation of financial statements in conformity with GAAP requires management to make estimates and judgments that affect the reported amounts of assets, liabilities, revenue, and expenses, and disclosures of contingent assets and liabilities. Critical accounting policies are those that we consider to be the most important in portraying our financial condition and results of operations and also require the greatest amount of judgments by management. Judgments or uncertainties regarding the application of these policies may result in materially different amounts being reported under different conditions or using different assumptions.
There have been no material changes to our critical accounting policies and estimates from those disclosed in the 2024 Form 10-K.
Recent Accounting Pronouncements
Refer to Item 1, Financial Statements, Note 2 (Summary of Significant Accounting Policies).
JOBS Act Election
We are currently an “emerging growth company,” as defined in the JOBS Act. Under the JOBS Act, emerging growth companies can delay adopting new or revised accounting standards until such time as those standards apply to private companies. We have elected to use this extended transition period for complying with new or revised accounting standards that have different effective dates for public and private companies until the earlier of the date we (i) are no longer an emerging growth company or (ii) affirmatively and irrevocably opt out of the extended transition period provided in the JOBS Act.
Item 3. Quantitative and Qualitative Disclosures About Market Risk
We are exposed to certain market risks arising from transactions in the normal course of our business. Such risks are principally associated with credit risk and interest rate risk.
Credit risk involves the possibility that a counterparty will not meet its obligations under a financial instrument or client contract, leading to a financial loss. Concentrations of credit risk with respect to our clients are limited due to our diversified client base.
We routinely assess the financial strength of our clients through a combination of third-party financial reports, credit monitoring, publicly available information, and direct communication with those clients. We establish payment terms with clients to mitigate credit risk and monitor its accounts receivable credit risk exposure. However, while we actively seek to ensure credit risk, there can be no assurance that in the future it will be able to obtain credit risk insurance at commercially attractive terms or at all.
Interest Rate Risk
Our exposure to interest rate risk is related to our First Lien Credit Facility, which bears interest at SOFR plus 2.00% as of September 30, 2025. A hypothetical 100 basis point increase or decrease in the current effective rate would have an impact on our interest expense of approximately $3.2 million for the three months ended September 30, 2025 or $9.4 million for the nine months ended September 30, 2025.
In order to limit exposure to risk, we maintain derivative instruments with creditworthy institutions to hedge against changing interest rate fluctuations. We utilize interest rate swap contracts and other non-derivative hedging instruments to manage such risk.
Item 4. Controls and Procedures
Disclosure Controls and Procedures
Under the supervision and with the participation of our management, including the Chief Executive Officer and Chief Financial Officer, we conducted an evaluation of the effectiveness of our disclosure controls and procedures (as such term is defined in Rule 13a-15(e) and 15d-15(e) under the Exchange Act) as of the end of the period covered by this report. Based on this evaluation, our Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures were effective as of such date. Our disclosure controls and procedures are designed to ensure that information required to be disclosed in the reports we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms and that such information is accumulated and communicated to management including the Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosures.
Changes in Internal Control Over Financial Reporting
There were no changes to our internal control over financial reporting (as defined in Rule 13a-15(f) under the Exchange Act) that occurred during the quarter ended September 30, 2025 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.
The information required with respect to this Part II, Item 1 can be found under Item 1, Financial Statements, Note 19 (Commitments and Contingencies), to the unaudited consolidated financial statements included in Part I, Item 1 of this Quarterly Report on Form 10-Q.
Item 1A. Risk Factors
There have been no material changes to the risk factors disclosed in the 2024 Form 10-K.
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds
None.
Item 3. Defaults Upon Senior Securities
None.
Item 4. Mine Safety Disclosures
Not applicable.
Item 5. Other Information
On
August 24, 2025
,
Eric Lee (Ric) Sinclair III
, our
Chief Business Officer
,
adopted
a trading plan intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act. Mr. Sinclair’s plan provides for (i) the exercise of up to 90,750 vested stock options and the associated sale of up
90,750
shares of the Company’s common stock; (ii) the exercise of vested stock options and the associated sale shares of the Company’s common stock with the actual number of such options and associated shares to be determined based on unsold shares from Mr. Sinclair's previously adopted trading plan dated February 19, 2025; and (iii) the exercise of options subject to performance-based vesting conditions and the associated sale of shares of the Company’s common stock, with the actual number of such options and associated shares to be determined based on the level of achievement of the performance criteria associated with the award. Mr. Sinclair’s trading plan will expire
December 31, 2026
, or upon the earlier sale of all the shares subject to the plan.
On
September 9, 2025
,
Craig Bridge
, our
Chief Transformation Officer
,
adopted
a trading plan intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act. Mr. Bridge’s plan provides for (i) the exercise of up to 112,485 vested stock options and the associated sale of up
112,485
shares of the Company’s common stock; (ii) the exercise of vested stock options and the associated sale shares of the Company’s common stock with the actual number of such options and associated shares to be determined based on unsold shares from Mr. Bridge's previously adopted trading plan dated November 27, 2024; and (iii) the exercise of options subject to performance-based vesting conditions and the associated sale of shares of the Company’s common stock, with the actual number of such options and associated shares to be determined based on the level of achievement of the performance criteria associated with the award. . Mr. Bridge’s trading plan will expire
December 31, 2026
, or upon the earlier sale of all the shares subject to the plan.
On
September 11, 2025
,
Melissa Miller
, our
Chief Marketing Officer
,
adopted
a trading plan intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act. Ms. Miller’s plan provides for (i) the exercise of up to 101,470 vested stock options and the associated sale of up
101,470
shares of the Company’s common stock; and (ii) the exercise of options subject to performance-based vesting conditions and the associated sale of shares of the Company’s common stock, with the actual number of such options and associated shares to be determined based on the level of achievement of the performance criteria associated with the award. Ms. Miller’s trading plan will expire
December 31, 2026
, or upon the earlier sale of all the shares subject to the plan.
On
September 11, 2025
,
Steven Oreskovich
, our
Chief Financial Officer
,
adopted
a trading plan intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act. Mr. Oreskovich’s plan provides for (i) the exercise of up to 519,277 vested stock options and the associated sale of up
519,277
shares of the Company’s common stock; and (ii) the exercise of options subject to performance-based vesting conditions and the associated sale of shares of the Company’s common stock, with the actual number of such options and associated shares to be determined based on the
level of achievement of the performance criteria associated with the award. Mr. Oreskovich’s trading plan will expire
December 31, 2026
, or upon the earlier sale of all the shares subject to the plan.
On
September 11, 2025
,
Christopher Schremser
, our
Chief Technology Officer
,
adopted
a trading plan intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act. Mr. Schremser’s plan provides for (i) the exercise of up to 454,682 vested stock options and the associated sale of up
454,682
shares of the Company’s common stock; and (ii) the exercise of options subject to performance-based vesting conditions and the associated sale of shares of the Company’s common stock, with the actual number of such options and associated shares to be determined based on the level of achievement of the performance criteria associated with the award. Mr. Schremser's trading plan will expire
December 31, 2026
, or upon the earlier sale of all the shares subject to the plan.
During the nine months ended September 30, 2025, none of the Company’s other directors or officers
adopted
, modified, or
terminated
a “Rule 10b5-1 trading arrangement” or “non-Rule 10b5-1 trading arrangement” as each term is defined in Item 408 of Regulation S-K.
XBRL Instance Document - the instance document does not appear in the interactive data file because its XBRL tags are embedded within the inline XBRL document.
† Management contract or compensatory plan or arrangement.
*
This exhibit shall not be deemed “filed” for purposes of Section 18 of the Exchange Act or otherwise subject to the liability of that Section. Such exhibit shall not be deemed incorporated into any filing under the Securities Act or the Exchange Act.
The agreements and other documents filed as exhibits to this report are not intended to provide factual information or other disclosure other than the terms of the agreements or other documents themselves, and you should not rely on them for that purpose. In particular, any representations and warranties made by the Company in these agreements or other documents were made solely within the specific context of the relevant agreement or document and may not describe the actual state of affairs as of the date they were made or at any other time.
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Lehi, Utah, on October 29, 2025.
Customers and Suppliers of Waystar Holding Corp.
Beta
No Customers Found
No Suppliers Found
Bonds of Waystar Holding Corp.
Price Graph
Price
Yield
Insider Ownership of Waystar Holding Corp.
company Beta
Owner
Position
Direct Shares
Indirect Shares
AI Insights
Summary Financials of Waystar Holding Corp.
Beta
(We are using algorithms to extract and display detailed data. This is a hard problem and we are working continuously to classify data in an accurate and useful manner.)